Inflammatory disease
MONDO:0021166A disease involving a pathogenic inflammatory response in the anatomical structure.
Also known as: anatomical structure inflammation, inflammation of anatomical structure, inflammatory disease, inflammatory disorder
10161 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 3431 trials in this tab.
-
Can hepatitis c be cured in just 4 weeks? a new trial puts it to the test
⭐️ CURE ⭐️ Recruiting nowThis pilot study is testing whether a 4-week course of two antiviral drugs—sofosbuvir plus glecaprevir/pibrentasvir—can cure chronic hepatitis C in people who have not been treated before and have only mild liver scarring. Participants who relapse after the short treatment will r…
Phase: PHASE4 • Sponsor: Kirby Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Pfizer launches massive trial of c. diff vaccine for seniors
⭐️ VACCINE ⭐️ Recruiting nowThis study tests whether a vaccine can prevent C. difficile infection in adults 65 and older. About 32,000 participants will receive either the vaccine or a placebo shot. The study will track infections and side effects over up to three and a half years.
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
New meningitis vaccine trial aims to shield babies from deadly infection
⭐️ VACCINE ⭐️ Recruiting nowThis Phase 3 trial tests a new vaccine designed to protect infants aged 3 to 5 months against four strains of meningococcal bacteria that cause meningitis and sepsis. About 880 healthy babies will receive either the experimental vaccine or a licensed comparator vaccine. Researche…
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine trial aims to protect babies
⭐️ VACCINE ⭐️ Recruiting nowThis Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis. About 1,040 healthy infants aged 6 to 11 months will receive either the experimental vaccine or a licensed comparator. Researchers will measure immune respon…
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine for toddlers shows promise in major trial
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new vaccine to protect young children (12-23 months old) against four types of meningococcal bacteria that can cause meningitis. About 1,040 toddlers will receive either the new vaccine or an existing one to see if the new vaccine is as safe and effective. The …
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
Can an updated COVID-19 vaccine keep up with the virus?
⭐️ VACCINE ⭐️ Recruiting nowThis trial is testing an updated version of the BNT162b2 COVID-19 vaccine in healthy adults aged 18 to 64. Participants will receive either the updated COVID-19 vaccine or a Tdap vaccine (for tetanus, diphtheria, and whooping cough) to compare safety and measure spike protein lev…
Phase: PHASE4 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
Can a genetically modified oral vaccine beat cholera?
⭐️ VACCINE ⭐️ Recruiting nowThis trial tests a new oral cholera vaccine called PanChol in healthy adults aged 18 to 55 in Zambia. The vaccine is designed to be safer and more effective than current options. Researchers will monitor participants for side effects and measure their immune response after vaccin…
Phase: PHASE1 • Sponsor: Centre for Infectious Disease Research in Zambia • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Can a new biologic drug prevent COPD Flare-Ups?
Disease control Recruiting nowThis phase 2 trial tests whether galvokimig, an experimental biologic drug, can reduce the number of moderate-to-severe COPD flare-ups in people with chronic bronchitis. About 400 adults aged 40 to 80 with moderate-to-severe COPD will receive either galvokimig or a placebo as an …
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a smartphone app replace physiotherapy for knee pain?
Disease control Recruiting nowThis trial tests whether a smartphone app-guided rehabilitation program (MOKneeTOR) is as effective as traditional hospital-based physiotherapy for people with knee osteoarthritis. Participants will be randomly assigned to either use the app for 24 weeks or attend outpatient phys…
Phase: NA • Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Engineered immune cells take on rare muscle disorders
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and red…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a Two-Pill combo calm the Gut's inflammatory fire?
Disease control Recruiting nowThis early-stage trial explores whether adding two experimental capsules, ND-12 and H-6, to standard mesalazine treatment can better control chronic inflammatory diarrhea in adults, including those with active ulcerative colitis. Participants will take the combination or a placeb…
Phase: EARLY_PHASE1 • Sponsor: The Second Hospital of Nanjing Medical University • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can an ancient herbal remedy tame rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether adding a Chinese herbal formula (Si Miao Xiao Bi Tang) to standard rheumatoid arthritis medication can improve symptoms. About 132 adults with active RA will receive either the herbal medicine or a placebo for 12 weeks. The main goal is to see if more peo…
Phase: PHASE2, PHASE3 • Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a diabetes drug fix liver energy problems in fatty liver disease?
Disease control Recruiting nowThis study looks at whether the diabetes drug pioglitazone can improve how the liver processes energy in people with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Researchers will measure liver mitochondrial function using special tracers before and after 16 weeks…
Phase: PHASE4 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for kidney disease: Zigakibart's Long-Term safety under study
Disease control Recruiting nowThis study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a simple patch stop diabetes device skin woes?
Disease control Recruiting nowThis trial tests whether a silicone-based or a hydrocolloid patch placed under insulin pumps or glucose monitors can prevent contact dermatitis from coming back in children aged 2-18. Participants will use different patches and attend visits for skin exams, ultrasounds, and quest…
Phase: NA • Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase: PHASE2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a new injection tame chronic hepatitis b?
Disease control Recruiting nowThis early-stage trial is evaluating an investigational drug called ACT201, given as an injection, to see if it is safe and tolerable. The study first tests single and multiple doses in healthy volunteers, then moves to people with chronic hepatitis B whose virus is already suppr…
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New liquid drug offers hope for kids with severe eczema
Disease control Recruiting nowThis 24-month study tests the long-term safety and effectiveness of abrocitinib, a liquid oral medication, in children aged 2 and older with moderate-to-severe atopic dermatitis (eczema). About 500 participants will receive the drug, with or without topical creams. The goal is to…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Engineered immune cells take on lupus kidney disease
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…
Phase: PHASE2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New shot could help eczema sufferers who Don't respond to steroids
Disease control Recruiting nowThis Phase 3 study tests whether lebrikizumab, an injectable drug, can safely and effectively treat nummular eczema in adults who haven't gotten enough relief from topical steroids or can't use them. About 270 participants will receive either lebrikizumab or a placebo injection. …
Phase: PHASE3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New eczema drug shows promise for kids in Late-Stage trial
Disease control Recruiting nowThis study tests whether abrocitinib, a liquid medicine, can improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and reduces i…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Could a targeted antibody outdo steroids for a rare kidney disease?
Disease control Recruiting nowThis phase IIa trial investigates whether obinutuzumab, a monoclonal antibody, can effectively treat adults with newly diagnosed minimal change disease, a kidney condition causing protein leakage and swelling. Participants receive either two doses of obinutuzumab or standard gluc…
Phase: PHASE2 • Sponsor: Medical University Innsbruck • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Talking through pain: could counseling unlock better exercise for knee arthritis?
Disease control Recruiting nowThis trial tests whether adding motivational interviewing—a counseling style that strengthens personal motivation—to a standard exercise program helps people with knee osteoarthritis feel more confident about exercising and managing pain. About 56 participants will be randomly as…
Phase: NA • Sponsor: Kutahya Health Sciences University • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for stubborn eczema? abrocitinib tested after biologics fail
Disease control Recruiting nowThis study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure impro…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Could family clinics cure hepatitis c as well as specialists?
Disease control Recruiting nowThis trial tests whether treating hepatitis C in primary care clinics, with non-specialist doctors, works as well as the standard specialist care in Brazil. It also evaluates the use of rapid tests and self-testing to find more people with the infection. The goal is to see if a s…
Phase: PHASE4 • Sponsor: Oswaldo Cruz Foundation • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New lung fibrosis drug SV001 enters first human safety trial
Disease control Recruiting nowThis early-phase study tests a new drug called SV001 in 53 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive a single dose of SV001 or a placebo. The goal is to check for side effects and measure drug levels in the blood. This is a fi…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to save sight in optic neuritis patients
Disease control Recruiting nowThis Phase 3 trial tests whether privosegtor, a neuroprotective drug, can improve vision recovery in people having their first episode of optic neuritis. About 210 adults aged 18 to 50 will receive either privosegtor or a placebo, both alongside standard steroid treatment. The ma…
Phase: PHASE3 • Sponsor: Oculis • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New study tracks how well risankizumab tames ulcerative colitis in daily life
Disease control Recruiting nowThis study follows 200 adults in Japan with moderate to severe ulcerative colitis who are already prescribed risankizumab by their doctor. Researchers will track how well the drug controls symptoms like diarrhea and rectal bleeding over up to 156 weeks. The goal is to see if the …
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take on multiple sclerosis and other nerve diseases
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill combo aims to protect vulnerable from severe COVID
Disease control Recruiting nowThis phase 3 trial tests a new antiviral pill, ibuzatrelvir, alone or with an IV drug (remdesivir) in 300 adults with weak immune systems who have mild-to-moderate COVID-19. The goal is to see if the combination prevents hospitalizations or worsening symptoms better than remdesiv…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Blood-Derived clot may regrow bone in gum disease
Disease control Recruiting nowThis trial compares two surgical approaches for treating furcation defects—bone loss where tooth roots split—in adults with periodontitis. One group receives a mix of advanced platelet-rich fibrin (A-PRF+) and bone graft material, while the other gets a collagen membrane with the…
Phase: NA • Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Psoriasis drug may be safe for patients with fatty liver
Disease control Recruiting nowThis study looks at how long adults with plaque psoriasis and a common liver condition called MASLD (fatty liver disease) continue taking the drug secukinumab. Researchers will review medical records from several Spanish hospitals to track treatment duration and changes in liver …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a gut microbiome transplant ease axial spondyloarthritis?
Disease control Recruiting nowThis trial tests whether transferring gut bacteria from a healthy donor (fecal microbiota transplantation, or FMT) can reduce disease activity in people with axial spondyloarthritis (axSpA) who haven't fully responded to biologic therapy. Participants receive a single enema with …
Phase: PHASE2 • Sponsor: University Hospital of North Norway • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill bring back skin color in vitiligo?
Disease control Recruiting nowThis study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to keep High-Risk COVID patients out of the hospital
Disease control Recruiting nowThis study tests an oral medication called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. Participants will receive either the drug or a placebo for 5 days, and researchers will track whether it reduces emerg…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Gene therapy takes on hepatitis b: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new gene therapy called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver scarr…
Phase: PHASE1 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Pregnant women with hepatitis c get new hope in drug trial
Disease control Recruiting nowThis study is testing the safety and drug levels of glecaprevir/pibrentasvir, a hepatitis C treatment, in 30 pregnant women with or without HIV. The goal is to see how the drug works during pregnancy and to monitor the health of both mothers and their infants up to 10 weeks after…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with severe gut disease: drug trial launches
Disease control Recruiting nowThis study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a disease that causes inflammation and sores in the colon. The goal is to see if the drug can safely help children feel better and achieve remission (no symptoms…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug shows promise for severe eczema in toddlers
Disease control Recruiting nowThis study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the conditio…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug avacopan under Long-Term safety review for vasculitis patients
Disease control Recruiting nowThis study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive injections and be monitored for 16…
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New study tests switch from IV to At-Home shots for gut disease
Disease control Recruiting nowThis study is testing the drug vedolizumab (Entyvio) in 400 adults with moderate to severe ulcerative colitis or Crohn's disease. Participants first receive the drug through an IV for 6 weeks, then switch to injections under the skin for the rest of the year. The main goal is to …
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New antibody aims to shield kidneys from autoimmune attack
Disease control Recruiting nowThis Phase 2 trial tests whether adding ALE.F02 to standard therapy can protect kidney function in people with ANCA-associated vasculitis, an autoimmune disease that attacks small blood vessels, often damaging the kidneys. About 80 participants will receive either a low, high, or…
Phase: PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a diet tame chronic hives in teens?
Disease control Recruiting nowThis trial asks whether adding a Mediterranean diet or a low-histamine diet to standard care can reduce disease activity and improve quality of life in teens aged 12-18 with chronic spontaneous urticaria (CSU), a condition causing persistent hives. Participants are randomly assig…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Recruiting nowThis Phase 3 trial tests whether mezagitamab, an injectable drug, can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a condition where immune complexes damage the kidneys. About 347 participants will receive either mezagitamab or a placeb…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill could ease severe childhood arthritis
Disease control Recruiting nowThis study tests a new oral medication, upadacitinib, in children aged 1 to 17 with active systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard in…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shoulder implant tracked for 10 years in 300 patients
Disease control Recruiting nowThis study is testing a shoulder replacement device in 300 people with shoulder arthritis, bone death, or rotator cuff tears. Participants receive the implant and are followed for 10 years to see how well it works and if it is safe. The goal is to improve pain and shoulder functi…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with colitis: risankizumab trial launches
Disease control Recruiting nowThis phase 3 study tests the drug risankizumab in about 120 children aged 2 to 18 with moderate to severe ulcerative colitis. The trial has three parts: an initial 12-week IV treatment period, a 52-week maintenance phase where patients get one of two doses by injection, and a lon…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Inhaled antibiotics aim to beat pneumonia in ECMO patients
Disease control Recruiting nowThis study investigates whether inhaling the antibiotic amikacin can better treat pneumonia caused by gram-negative bacteria in patients on veno-arterial ECMO (a heart-lung bypass machine). Standard antibiotics often fail in these patients, possibly because the bypass reduces blo…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a drug calm severe eczema itch when the rash is mild? a new study investigates
Disease control Recruiting nowThis study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …
Sponsor: Sanofi • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New antibody cocktail takes on tough lupus kidney disease
Disease control Recruiting nowThis early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Gene-Editing breakthrough aims to fix immune cells in rare disease
Disease control Recruiting nowThis early-stage trial tests a new gene-editing approach for X-linked chronic granulomatous disease (X-CGD), a rare immune disorder. Researchers will collect stem cells from 10 adult male participants, use base editing to correct the genetic mutation, and return the cells after m…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Bone-Sparing hip implant outperform traditional replacement?
Disease control Recruiting nowThis trial tests whether a new type of hip resurfacing implant, called the H1, can be as successful as a standard total hip replacement for people with hip arthritis. Participants will receive either the H1 implant or a traditional replacement, and researchers will compare their …
Phase: NA • Sponsor: Embody Orthopaedic Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New inhaled drug aims to fight deadly lung scarring
Disease control Recruiting nowThis Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…
Phase: PHASE2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for heart lining pain: can CardiolRx keep flare-ups away?
Disease control Recruiting nowThis study tests whether the drug CardiolRx can prevent another episode of pericarditis (inflammation around the heart) in people who have had repeated attacks. About 110 adults who have been stable on an IL-1 blocker for at least a year will stop that medication and receive eith…
Phase: PHASE3 • Sponsor: Cardiol Therapeutics Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New eczema drug TRB-061 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called TRB-061 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study checks for safety, side effects, and how the drug moves through the body. Participants receive either TRB-061 or a placebo as injectio…
Phase: PHASE1 • Sponsor: TRex Bio, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can one injection beat back pain? a trial aims to find out
Disease control Recruiting nowThis trial investigates different types of steroid injections for back, neck, and related pain to see which are most effective and safe. It compares various steroids, doses, and injection sites, including epidural and facet joint injections. The study measures pain relief and fun…
Phase: PHASE4 • Sponsor: Igor Wilderman. MD • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to tame rare blood vessel disease
Disease control Recruiting nowThis Phase 3 trial is testing whether adding BDB-001 to standard treatments (cyclophosphamide, azathioprine, rituximab, or prednisone) helps more people with ANCA-associated vasculitis achieve remission. The study plans to enroll 300 adults with active GPA or MPA. Participants wi…
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a tiny ear tube offer lasting relief for middle ear infections?
Disease control Recruiting nowThis study is checking how well the Solo+ tympanostomy tube works in people with middle ear infections. Researchers will review doctor notes, monitor how the tubes function after surgery, and ask patients or their parents about their experience. The goal is to gather real-world i…
Sponsor: AventaMed DAC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a simpler dental procedure spare kids from a painful root canal?
Disease control Recruiting nowThis trial tests whether a simpler dental procedure called pulpotomy works as well as the standard pulpectomy for treating severe tooth decay in children's baby molars. Pulpotomy removes only the infected part of the pulp and seals it, while pulpectomy removes the entire pulp and…
Phase: NA • Sponsor: Qatar University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo aims to tame tough Crohn's
Disease control Recruiting nowThis study tests if the drug vorinostat is safe and can help people with moderate-to-severe Crohn's disease by reducing gut inflammation. Participants who respond well may then receive a maintenance treatment with ustekinumab for up to two years. The goal is to control symptoms a…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can saving the meniscus save knees from osteoarthritis?
Disease control Recruiting nowThis study follows 300 people with a specific type of knee injury called a displaced bucket-handle meniscus tear, which can lock the knee and damage the joint. Researchers will compare two surgical approaches: repairing the torn meniscus with stitches versus removing the damaged …
Sponsor: Region Skane • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Kids' diarrhea: drug plus fluids tested
Disease control Recruiting nowThis study tests how the drug rifaximin (Xifaxan) works in children aged 6 to 11 with acute diarrhea likely caused by bacteria. Half the children get the drug plus oral rehydration therapy, the other half get rehydration alone. Researchers want to see if adding the drug helps dia…
Phase: PHASE4 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Breathing technique may outperform spirometry for smog pneumonia recovery
Disease control Recruiting nowThis trial tests whether a specific breathing exercise, the Buteyko technique, can improve oxygen levels, reduce breathlessness, and enhance exercise ability in patients with pneumonia caused by smog. It compares this approach to incentive spirometry, a standard device that encou…
Phase: NA • Sponsor: Lahore University of Biological and Applied Sciences • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can Ultrasound-Guided shock waves dissolve shoulder calcium deposits?
Disease control Recruiting nowThis trial investigates whether using real-time ultrasound to guide shock wave therapy improves outcomes for people with calcific tendinitis of the shoulder, a painful condition where calcium deposits form in the rotator cuff tendons. Participants aged 20 to 70 with confirmed dep…
Phase: NA • Sponsor: Taipei Medical University WanFang Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Double drug attack on ulcerative colitis shows promise
Disease control Recruiting nowThis study tests whether combining two drugs—vedolizumab and tofacitinib—can quickly bring moderate to severe ulcerative colitis under control. About 65 adults will receive both drugs for 8 weeks, and those who respond will continue on vedolizumab alone for nearly a year. The goa…
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Mouthwash showdown: can a new formula fight gum disease without staining teeth?
Disease control Recruiting nowThis study tests whether a chlorhexidine mouthwash with an anti-discoloration system (ADS) can prevent gum inflammation better than a placebo. Healthy volunteers will stop brushing for three weeks and use only the mouthwash to see how well it controls plaque and gingivitis. The g…
Phase: NA • Sponsor: University of Bern • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to slow kidney failure in rare genetic disease
Disease control Recruiting nowThis study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that damages kidneys, hearing, and eyes. The drug works by blocking a protein thought to cause kidney injury, with the goal of slowing the loss of ki…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Three-Drug combo quiet lupus kidney flares?
Disease control Recruiting nowThis trial tests whether adding voclosporin to standard lupus nephritis treatment (mycophenolate mofetil and prednisolone) reduces kidney inflammation faster and more completely than standard treatment alone. Adults with active lupus nephritis will be randomly assigned to either …
Phase: PHASE4 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot could help tame stubborn Graves' disease
Disease control Recruiting nowThis study tests a drug called efgartigimod, given as a shot under the skin, for adults with Graves' disease whose thyroid levels are still too high despite taking standard antithyroid drugs. About 230 people will take part, and some will get the drug while others get a placebo. …
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a new toothpaste tame gum disease?
Disease control Recruiting nowThis study tests whether an experimental toothpaste containing stannous fluoride can reduce gum inflammation and plaque buildup better than a standard fluoride toothpaste. About 110 adults with mild to moderate gingivitis will brush twice daily for 8 weeks. Researchers will measu…
Phase: NA • Sponsor: HALEON • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without lifelong pills
Disease control Recruiting nowThis trial tests a new drug called IMVT-1402 for adults with Graves' disease, a condition where the thyroid is overactive. The study will include 210 participants who still have high thyroid levels despite taking standard medications. Participants will receive either one of two d…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure s…
Phase: PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a saf…
Phase: PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New oral option may offer relief for hereditary angioedema attacks
Disease control AVAILABLEThis program provides access to an experimental oral medication called deucrictibant for people with hereditary angioedema (HAE) who have no satisfactory alternative treatments for acute attacks. Eligible participants, aged 12 to 75, take the capsule as needed to manage swelling …
Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase
Disease control Recruiting nowThis study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not improved with or cannot take standard TNF-blocker medications. About 600 participants will receive either sonelokimab, a placebo, or an existing drug (risankizumab) for comparis…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill aims to break the cycle of repeat c. diff infections
Disease control Recruiting nowThis phase 2 trial tests an oral drug called ibezapolstat in 20 people who have had three or more C. diff infections in the past year. The goal is to see if the drug can cure the current infection and reduce the chance of it coming back. Participants will take the drug twice a da…
Phase: PHASE2 • Sponsor: Acurx Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new shoulder implant restore Pain-Free movement?
Disease control Recruiting nowThis study follows 60 adults who receive a total shoulder replacement using the PRIMA humeral stem, either in an anatomic or reverse configuration. The goal is to measure changes in shoulder function, pain, and quality of life over 24 months, as well as how well the implant holds…
Sponsor: Limacorporate S.p.a • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug trial aims to tame gut disease in kids
Disease control Recruiting nowThis study tests a daily pill called filgotinib in 80 children aged 8 to 17 with moderate to severe ulcerative colitis, a chronic gut disease. The goal is to see if the drug can reduce inflammation and help children feel better. All participants receive the drug, and the study tr…
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cell therapy HN2301 enters human trials for autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a pill reverse eye bulging in thyroid eye disease?
Disease control Recruiting nowThis clinical trial tests whether an oral medication called linsitinib can reduce eye bulging (proptosis) in people with moderate to severe active thyroid eye disease (TED). Participants will take either linsitinib or a placebo twice daily for 24 weeks. The main goal is to see if…
Phase: PHASE3 • Sponsor: Sling Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a common amino acid outperform chemotherapy cream to restore skin color?
Disease control Recruiting nowThis trial tests whether applying tyrosine or 5-fluorouracil to the skin, combined with a fractional erbium YAG laser, can help restore color in people with focal vitiligo. Vitiligo is an autoimmune condition that causes white patches by destroying pigment-making cells. The study…
Phase: EARLY_PHASE1 • Sponsor: Aswan University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria and minerals: a new hope for ulcerative colitis remission?
Disease control Recruiting nowThis trial is testing whether adding a Lactobacillus probiotic or a trace element supplement to standard ulcerative colitis treatment can help keep the disease in remission. About 132 adults with mild to moderate ulcerative colitis will be randomly assigned to one of three groups…
Phase: PHASE4 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New shot aims to stop repeat heart sac inflammation
Disease control Recruiting nowThis study tests an injected drug called KPL-387 in 165 people with recurrent pericarditis, a condition where the sac around the heart becomes inflamed again and again. The goal is to see if KPL-387 can reduce flare-ups and pain better than a placebo. Participants must have sympt…
Phase: PHASE2, PHASE3 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug aims to calm kidney attack by antibodies
Disease control Recruiting nowThis study tests a drug called surovatamig in 43 adults with primary membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The drug is given as a shot under the skin. Researchers want to see if it is safe and can reduce protein in the urine, which i…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without daily pills
Disease control Recruiting nowThis phase 2b trial tests an experimental drug called IMVT-1402 in 240 adults with Graves' disease whose thyroid is still overactive despite standard treatment. The goal is to see if the drug can help patients achieve normal thyroid hormone levels and stop taking antithyroid medi…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New shot aims to keep pericarditis Flare-Ups at bay
Disease control Recruiting nowThis study tests a new drug called KPL-387 in 80 people with well-controlled recurrent pericarditis (inflammation around the heart). The goal is to see if patients can safely switch from their current treatments to KPL-387 alone and still prevent flare-ups. The trial will measure…
Phase: PHASE2 • Sponsor: Kiniksa Pharmaceuticals International, plc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis pain in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug zasocitinib (TAK-279) can reduce joint swelling and pain in people with active psoriatic arthritis. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The main goal is to see if more people on the …
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Malaria drug artesunate tested for lung scarring
Disease control Recruiting nowThis early-stage trial tests whether artesunate, a drug used for malaria, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Fifteen adults with IPF will receive either artesunate capsules or a placebo for 12 week…
Phase: PHASE1 • Sponsor: Joseph C. Wu • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New ointment aims to restore skin color in vitiligo
Disease control Recruiting nowThis Phase 3 trial tests whether an ointment called MH004 can help restore skin color in people with non-segmental vitiligo. The study includes adolescents and adults aged 12 to 75 with facial vitiligo. Participants apply the ointment twice daily for 24 weeks, and researchers mea…
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill could clear psoriasis in teens
Disease control Recruiting nowThis study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Targeting the immune system: a new antibody may free Graves' patients from daily drugs
Disease control Recruiting nowThis phase 2 trial tests whether felzartamab, an antibody that targets immune cells producing harmful antibodies, can restore normal thyroid function in people with Graves' disease. Participants will receive either felzartamab or a placebo alongside their usual anti-thyroid drugs…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis without biologics
Disease control Recruiting nowThis Phase 3 study tests whether the oral drug zasocitinib (TAK-279) can improve symptoms of active psoriatic arthritis in people who have never used biologic treatments. About 1,088 adults will receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. Th…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Tailored therapy may save colons in severe ulcerative colitis
Disease control Recruiting nowThis trial is testing whether personalized, adaptive treatment strategies can help people hospitalized with acute severe ulcerative colitis. The approach adjusts medication based on how each patient responds, aiming to improve outcomes and reduce the need for colon removal. The s…
Phase: PHASE4 • Sponsor: Berinstein, Jeffrey • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a once-every-few-weeks IV infusion tame rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether giving sarilumab (Kevzara) through an IV with longer intervals between doses is safe and works well for adults with moderate-to-severe rheumatoid arthritis. Participants receive the drug intravenously, with or without other standard arthritis medications.…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody drug takes aim at rheumatoid arthritis in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KT502 in 27 adults with moderate to severe rheumatoid arthritis. The drug is designed to deplete certain immune cells (B cells) that contribute to joint inflammation. The main goal is to check safety and find the right dose, not yet …
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug BBD-1 shows promise for painful skin and kidney disease
Disease control Recruiting nowThis study tests a new drug, BBD-1, against standard steroids for IgA vasculitis, a disease that causes purple spots on the skin, joint pain, and can damage the kidneys. The trial will enroll 30 adults with confirmed IgA vasculitis. The goal is to see if BBD-1 can clear skin spot…
Phase: PHASE2 • Sponsor: Qifeng Zhang • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Giant cell arteritis patients may be able to reduce treatment, study suggests
Disease control Recruiting nowThis study looks at whether people with giant cell arteritis (GCA) who are in remission can safely stop or lower their dose of tocilizumab (Actemra). About 78 adults who have been on high-dose tocilizumab for at least a year and off steroids for three months will either stop the …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New weekly shot aims to stop liver disease from getting worse
Disease control Recruiting nowThis Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a diabetes drug help heal fatty livers?
Disease control Recruiting nowThis study looks at how the liver responds to food and a drug called semaglutide in people with non-alcoholic fatty liver disease (NAFLD). About 84 adults, including healthy volunteers, will take part. Researchers will check if semaglutide can reduce liver fat and damage over 30 …
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can diabetes drugs tame joint inflammation in psoriatic arthritis?
Disease control Recruiting nowThis trial asks whether GLP-1 medications, commonly used for type 2 diabetes and weight loss, can better control psoriatic arthritis symptoms than nutrition counseling alone. Adults with psoriatic arthritis who also have obesity and type 2 diabetes will be randomly assigned to re…
Phase: PHASE4 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug tulisokibart aims to ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. Researchers will compare different doses of the drug to a placebo in 140 adults to see if it improves symptoms like joint tenderness an…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New weekly shot could reverse liver damage in MASH patients
Disease control Recruiting nowThis phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for kids with arthritis: Long-Term drug study launches
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of the drug filgotinib in children and adolescents aged 8 to 17 with juvenile idiopathic arthritis. Participants must have already completed a previous filgotinib study and shown improvement. The goal is to see if the d…
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New inhaled therapy aims to slow lung scarring in IPF
Disease control Recruiting nowThis study tests an inhaled version of the drug nintedanib (called AP02) in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 160 adults aged 40 and older who are not currently on IPF treatment will take either a low o…
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can tailored fluid dosing tame pancreatitis?
Disease control Recruiting nowThis trial tests whether giving fluids based on real-time changes in stroke volume—a measure of how much blood the heart pumps—can improve outcomes in people with moderate to severe acute pancreatitis. Standard care uses a fixed weight-based amount, which can sometimes lead to fl…
Phase: NA • Sponsor: University of Southern California • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug zigakibart aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce signs of kidney damage and slow disease progression. Participants must have a recent kidney biopsy and persistent protein in their urine despite stan…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a simple pill improve recovery after hip replacement?
Disease control Recruiting nowThis study tests whether taking oral tranexamic acid for three days after hip replacement surgery can reduce pain, swelling, and help patients walk sooner. About 101 adults with end-stage osteoarthritis will receive the drug or placebo. The goal is to see if this simple pill impr…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a stem cell shot rebuild Worn-Out knees?
Disease control Recruiting nowThis study tests an experimental stem cell injection called FURESTEM-OA-Kit in people with knee osteoarthritis who previously received a placebo in an earlier trial. The goal is to see if the injection is safe and can improve knee pain, stiffness, and function. Participants will …
Sponsor: Kang Stem Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to tame immune system in lupus and Sjogren's
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to deplete overactive B cells, which are part of the immune system that cause inflammation and symptoms. Participants receive two doses by IV, 2…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can green tea gel help heal gum pockets?
Disease control Recruiting nowThis trial tests whether a gel made from green tea extract (EGCG) can improve the treatment of stage II periodontitis, a moderate form of gum disease. Thirty adults with gum pockets will receive either the gel or a placebo gel, injected into the gums after standard deep cleaning.…
Phase: PHASE1 • Sponsor: Mansoura University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill aims to slow lung scarring in IPF patients
Disease control Recruiting nowThis phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…
Phase: PHASE2 • Sponsor: Contineum Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New antibody drug aims to protect kidneys in PMN patients
Disease control Recruiting nowThis Phase 3 study tests a new drug called felzartamab in 180 people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. Felzartamab is a lab-made antibody designed to stop that attack. The study compares felzartamab to …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Brain training targets impulse control to fight OCD and related disorders
Disease control Recruiting nowThis study tests whether a computerized training program designed to improve response inhibition — the ability to stop an automatic action — can reduce symptoms in people with obsessive-compulsive disorder, trichotillomania (hair-pulling), or skin-picking disorder. Participants a…
Phase: NA • Sponsor: University of Wisconsin, Milwaukee • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New skin disease drug enters first human trials
Disease control Recruiting nowThis study tests a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy volunteers and people with immune-related skin diseases. The study is split into two parts: single dose in healthy people and mult…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can balance training ease stubborn heel pain?
Disease control Recruiting nowThis trial tests whether adding a supervised proprioception (balance) exercise program to standard stretching exercises improves pain, function, and disability in people with chronic plantar fasciitis, a common cause of heel pain. About 105 adults aged 18 to 65 with symptoms last…
Phase: NA • Sponsor: Karamanoğlu Mehmetbey University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New antibody drug aims to slow lung scarring in IPF
Disease control Recruiting nowThis phase 2 trial tests whether MTX-463, an antibody that blocks a protein linked to scarring, can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF). About 164 adults with IPF will receive either the drug or a placebo for 24 weeks. The main goal is to…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising new treatment for rare Muscle-Weakening disease enters human trials
Disease control Recruiting nowThis study tests a drug called ublituximab for people with a rare autoimmune disease that causes severe muscle weakness. The goal is to see if adding this drug to standard treatment improves muscle strength and function more than standard treatment alone. About 30 adults with ear…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New inhaled drug for lung scarring moves to Long-Term safety check
Disease control Recruiting nowThis study looks at the long-term safety of an inhaled drug (AP01) for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. About 340 participants will receive the drug and be monitored for side effects …
Phase: PHASE2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill for chronic hives enters first human tests
Disease control Recruiting nowThis early-stage trial tests a single oral dose of HRS-3095, a new drug for chronic spontaneous urticaria (chronic hives), in 36 healthy adults. The main goal is to check safety and how the drug moves through the body. Results will guide future studies in patients with hives.
Phase: EARLY_PHASE1 • Sponsor: Atridia Pty Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a simple asthma drug prevent a dangerous immunotherapy side effect?
Disease control Recruiting nowThis study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug cevostamab enters early human testing for lupus
Disease control Recruiting nowThis early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for kids with IBD: Long-Term drug trial launches
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of mirikizumab in 150 children and adolescents with moderate-to-severe ulcerative colitis or Crohn's disease. Participants who completed earlier mirikizumab studies can join. The trial lasts about 172 weeks and aims to see i…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug shows promise in reversing liver scarring in major trial
Disease control Recruiting nowThis Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Botox injections could tame painful skin disease
Disease control Recruiting nowThis study is testing whether Botox injections can reduce inflammation in people with hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. Researchers believe that blocking certain nerve signals may calm the immune response. The study will enroll 20 …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo aims to tame tough autoimmune diseases
Disease control Recruiting nowThis study tests two medications, inebilizumab and blinatumomab, in adults with active lupus (with kidney inflammation) or hard-to-treat rheumatoid arthritis. The goal is to see if these drugs are safe and can help control the diseases. About 220 people will take part. This is no…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug trial aims to protect Kids' kidneys from IgA nephropathy
Disease control Recruiting nowThis phase 3 trial tests the drug atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The study measures whether atrasentan reduces protein in the urine, a sign of kidney damage, over 36 weeks. All participants receive th…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New antibiotic lefamulin takes on Drug-Resistant pneumonia
Disease control Recruiting nowThis study looks at how safe and effective the antibiotic lefamulin is for treating community-acquired pneumonia (CAP) in Chinese patients. CAP is a lung infection caught outside of hospitals, and many common antibiotics are becoming less effective due to drug resistance. Lefamul…
Sponsor: Marubeni Pharmaceuticals (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New eczema drug ZL-1503 enters first human safety trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meani…
Phase: PHASE1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cream could ease painful skin condition lichen sclerosus
Disease control Recruiting nowThis study tests a cream called delgocitinib for lichen sclerosus, a skin condition that causes itching, pain, and scarring in the genital area. About 652 adults with mild to severe disease will apply the cream twice daily for up to 52 weeks. Researchers will check if the cream i…
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can switching IBD meds heal the gut when symptoms are quiet?
Disease control Recruiting nowThis study looks at people with inflammatory bowel disease (Crohn's or ulcerative colitis) who feel fine but still have moderate to severe inflammation inside their gut. It compares two approaches: switching to a different targeted medication versus staying on the current one. Th…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid in Graves' disease
Disease control Recruiting nowThis study tests whether BHV-1300 can help adults with Graves' disease achieve normal thyroid function without antithyroid drugs. Participants receive either BHV-1300 or a placebo via injection. The main goal is to see if more people on BHV-1300 have normal thyroid hormone levels…
Phase: PHASE3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for kids with arthritis: baricitinib Long-Term trial underway
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug baricitinib for children aged 1 to 17 with juvenile idiopathic arthritis (JIA). It includes 190 participants who have already taken baricitinib in a previous study. Researchers will monitor side effects and ho…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Phase: PHASE2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can community hospitals in zambia master severe disease care?
Disease control Recruiting nowThis trial tests a new model of care called PEN-Plus, which brings specialized treatment for severe chronic diseases like diabetes, heart conditions, and sickle cell disease to first-level hospitals in Zambia. The goal is to train local health workers and set up clinics to manage…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New oral drug aims to cut dangerous COPD exacerbations
Disease control Recruiting nowThis Phase 2 study tests whether a once-daily oral tablet called EXPD-101 can reduce the number of moderate to severe COPD flare-ups in people with chronic bronchitis. Participants must have had at least two moderate or one severe exacerbation in the past year. The trial compares…
Phase: PHASE2 • Sponsor: Expedition Therapeutics, Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New pill for chronic hives tested in everyday clinics
Disease control Recruiting nowThis study follows 470 adults with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will track how well it controls symptoms and any side effects over two years in real-world clinics. The goal is to see if remibrutinib works as well out…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can less be more? trial tests cutting RA medication doses
Disease control Recruiting nowThis trial asks whether people with rheumatoid arthritis who have low disease activity can safely reduce their JAK inhibitor dose without losing control of their symptoms. Participants will either follow a step-by-step dose-tapering plan or continue their usual full-dose medicati…
Phase: PHASE4 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Immune cell therapy takes on autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for rare kidney patients: Long-Term drug trial shows promise
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of a drug called iptacopan for people with two rare kidney diseases: C3 glomerulopathy and IC-MPGN. About 225 adults who have already completed a previous iptacopan study will take the drug for an extended period. The goa…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
Disease control Recruiting nowThis trial tests whether a 12-week dietary intervention can improve gut health, reduce inflammation, and enhance quality of life in adults with ulcerative colitis who are in remission. Participants are randomly assigned to a Mediterranean diet, a Mediterranean diet combined with …
Phase: NA • Sponsor: Pontificia Universidad Catolica de Chile • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New shot aims to recolor white patches in vitiligo
Disease control Recruiting nowThis study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New eczema pill shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental pill called ENV-294 for adults with moderate-to-severe atopic dermatitis (eczema). About 200 participants will take either one of three doses of ENV-294 or a placebo daily for 12 weeks. Researchers will measure changes in eczema severity, symptoms…
Phase: PHASE2 • Sponsor: Enveda Therapeutics • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for kids with psoriatic arthritis: apremilast trial begins
Disease control Recruiting nowThis Phase 3 study tests whether the drug apremilast (Otezla) can safely reduce joint inflammation and pain in children aged 5 to 17 with active juvenile psoriatic arthritis. About 60 participants will receive either apremilast or a placebo pill for 16 weeks. The main goal is to …
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
HS patients who responded to drug get extended access in new study
Disease control Recruiting nowThis study offers continued treatment with povorcitinib for up to 600 adults with hidradenitis suppurativa who completed a prior trial and saw benefit. The main goal is to track side effects over time, with a secondary focus on reducing skin abscesses, nodules, and tunnels. Parti…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a drug combo shield lungs from radiation damage?
Disease control Recruiting nowThis study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this red…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Eczema drug afimkibart tested for Long-Term safety in new study
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema) who have already taken it in earlier studies. About 120 adults will be followed to see how well the drug controls their eczema over time and what side effe…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New knee implant aims for 10-Year durability in arthritis patients
Disease control Recruiting nowThis study is testing the LEGION Medial Stabilized knee implant in 144 people who need total knee replacement due to arthritis or joint damage. The goal is to see how well the implant holds up over 10 years without needing revision surgery. Participants will receive one of three …
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for teens with painful skin condition: experimental drug povorcitinib under study
Disease control Recruiting nowThis study tests an oral drug called povorcitinib in 40 adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils and tunnels. Over 54 weeks, researchers will check the drug's safety, how the body processes it,…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New cream could ease painful skin condition
Disease control Recruiting nowThis early-stage trial tests a cream called ruxolitinib on people with hidradenitis suppurativa, a condition causing painful lumps under the skin. The study includes 24 adults and teens and focuses on safety and how much of the drug gets into the body. Participants apply the crea…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo targets fatty liver in major trial
Disease control Recruiting nowThis study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…
Phase: PHASE2 • Sponsor: Eccogene • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New bacterial vaginosis treatment aims to rebalance vaginal flora
Disease control Recruiting nowThis study tests a new treatment called FB301 in 120 women aged 18-45 with bacterial vaginosis (BV). Before FB301, some women will receive an antibiotic or a vaginal wash to see if that helps restore healthy bacteria. The goal is to improve the balance of good bacteria in the vag…
Phase: PHASE2 • Sponsor: Freya Biosciences ApS • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug hopes to tackle MASH cirrhosis
Disease control Recruiting nowThis study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to halt lung damage in autoimmune patients
Disease control Recruiting nowThis study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill vs. injection: which works better for kids with severe eczema?
Disease control Recruiting nowThis study tests two medicines for children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. One group gets upadacitinib (a daily pill or liquid), the other gets dupilumab (an injection every 2 or 4 weeks). The goal is to see which better reduces skin …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New lung fibrosis pill tested for Long-Term safety in 1,700 patients
Disease control Recruiting nowThis study tests the long-term safety of the drug nerandomilast in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). All 1,700 participants have already taken the drug in a previous study. They will take nerandomilast tablets for up to 1 yea…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a simple wash save a tooth that hurts?
Disease control Recruiting nowThis trial tests whether using calcium hypochlorite or sodium hypochlorite to clean the pulp wound during a partial pulpotomy can improve the success of saving painful, deeply decayed permanent molars. Adults aged 18-40 with symptomatic irreversible pulpitis will undergo the proc…
Phase: NA • Sponsor: Postgraduate Institute of Dental Sciences Rohtak • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for gut disease: experimental drugs enter human trials
Disease control Recruiting nowThis phase 2 study is testing two new drugs — mirikizumab (given by IV or injection) and LY4395089 (a pill) — in 60 adults with moderately to severely active ulcerative colitis or Crohn's disease. The goal is to see if these treatments are safe and can help control the disease. T…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Stem cell gel could offer new hope for knee arthritis sufferers
Disease control Recruiting nowThis Phase 3 trial tests whether a gel made from donated umbilical cord stem cells (CARTISTEM) can reduce pain and improve knee function better than a simple surgical cleanup (debridement) in people with knee cartilage damage and osteoarthritis. About 300 adults aged 18-75 with m…
Phase: PHASE3 • Sponsor: Medipost, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo pill aims to tame stubborn ulcerative colitis
Disease control Recruiting nowThis study tests whether adding a new oral drug, LY4268989, to the existing treatment mirikizumab works better than mirikizumab alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive either the combination or mirikizumab plus a placebo fo…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug aims to stop swelling attacks in hereditary angioedema
Disease control Recruiting nowThis phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main go…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New shot aims to tame hepatitis b without daily pills
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop the…
Phase: PHASE2 • Sponsor: AusperBio Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for nerve disease: immune therapy trial targets long-term control
Disease control Recruiting nowThis study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher o…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
Disease control Recruiting nowThis early study tests whether a liquid form of the drug avacopan can be safely given through a feeding tube to critically ill patients with ANCA vasculitis who have severe lung bleeding and need a ventilator. The main goal is to measure how the drug levels change in the blood ov…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a pill shield the brain and kidneys during heart surgery?
Disease control Recruiting nowThis trial tests whether vericiguat, a drug that relaxes blood vessels, can protect the body during heart surgery. About 170 adults scheduled for open-heart surgery will receive either vericiguat or a placebo starting two days before the operation. Researchers will measure blood …
Phase: PHASE4 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Promising drug combo may stop painful flare-ups in rare bone disease
Disease control Recruiting nowThis study looks at whether anti-inflammatory drugs (like anakinra or canakinumab) can reduce painful flare-ups and prevent extra bone growth in people with a rare genetic condition called fibrodysplasia ossificans progressiva (FOP). Eleven people with severe FOP will be tracked …
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy targets gut disease and obesity together
Disease control Recruiting nowThis phase 3 trial tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an anti-inflammatory drug) helps people with moderate-to-severe ulcerative colitis who are also overweight or obese. The goal is to see if the combination can reduce both gut symptoms and bod…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for ulcerative colitis: experimental drug enters human trials
Disease control Recruiting nowThis study tests a new drug called BI 3032950 in 80 adults with moderate to severe ulcerative colitis who haven't improved on other treatments. In the first part, the drug is given by IV every 4 weeks for 12 weeks. Those who respond then receive injections under the skin every 4 …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New kidney drug shows promise in reducing protein leakage
Disease control Recruiting nowThis study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill could tame ulcerative colitis Flare-Ups
Disease control Recruiting nowThis study tests an oral drug called LY4268989 (MORF-057) in adults with moderate-to-severe ulcerative colitis. About 1,431 participants will receive either the drug or a placebo for up to 108 weeks. The goal is to see if the drug can safely help control the disease and improve s…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental drug aims to reverse liver damage in rare triple condition
Disease control Recruiting nowThis study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.
Phase: PHASE2 • Sponsor: Kiminori Kimura, MD • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug aims to reverse liver damage in MASH cirrhosis
Disease control Recruiting nowThis Phase 3 study tests an experimental drug called pegozafermin in 762 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants receive weekly injections of the drug or a placebo for about two years. The goal is to see if the drug can improve l…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for ulcerative colitis: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation in the colon. About 350 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goal is to se…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Microembolization may outlast steroid shots for frozen shoulder
Disease control Recruiting nowThis study compares two treatments for frozen shoulder: a newer procedure called transcatheter arterial microembolization (TAME) and standard corticosteroid injections. TAME aims to reduce pain by blocking abnormal blood vessels in the shoulder, while steroids work by calming inf…
Phase: NA • Sponsor: Shin Kong Wu Ho-Su Memorial Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental drug aims to reverse liver scarring in MASH cirrhosis
Disease control Recruiting nowThis Phase 3 trial tests whether efimosfermin alfa can improve liver fibrosis in adults with compensated cirrhosis caused by MASH (a fatty liver disease). Participants receive either the drug or a placebo via injection. The main goal is to see if liver scarring improves by at lea…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for toddlers with esophagus inflammation: dupilumab trial launches
Disease control Recruiting nowThis study tests the drug dupilumab in children as young as 6 months who have active eosinophilic esophagitis (EoE), a condition that causes inflammation in the esophagus and can make eating difficult. The goal is to see if the drug is safe and effective over 24 weeks. About 20 c…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Stop the pills when symptoms vanish? landmark trial for Kids' infections
Disease control Recruiting nowThis study tests whether children with bacterial infections like urinary tract infections, cellulitis, or pneumonia can safely stop oral antibiotics once their symptoms go away, instead of finishing the entire course. About 200 children aged 1 to 17 who have already received IV a…
Phase: PHASE4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental drug aims to stop liver failure in MASH cirrhosis
Disease control Recruiting nowThis phase 3 study tests whether an experimental drug called efimosfermin alfa can prevent serious liver complications in adults with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Participants receive either the drug or a placebo as a shot …
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill aims to plug protein leak in kidney patients
Disease control Recruiting nowThis study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein to leak into urine. Participants take the drug twice daily for a year. The main goal is to see if it safely reduces protein leve…
Phase: PHASE2 • Sponsor: Everest Medicines (China) Co.,Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new injection tame hereditary swelling attacks?
Disease control AVAILABLEThis program provides access to an investigational drug called donidalorsen for people with hereditary angioedema (HAE), a genetic condition that causes sudden, painful swelling in various body parts. The drug is given as a monthly or every-other-month injection under the skin. I…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can immune therapy help rare muscle disorder?
Disease control Recruiting nowThis phase 2 trial tests whether intravenous immunoglobulin (IVIG) can help people with a rare autoimmune muscle disease called anti-HMGCR immune-mediated necrotizing myopathy. Twelve participants will receive either IVIG or a placebo every 4 weeks for 12 weeks, then all may rece…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a targeted therapy tame rare kidney diseases in daily practice?
Disease control Recruiting nowThis study looks at how well the medication pegcetacoplan works and how safe it is for people with two rare kidney conditions: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Researchers will follow about 150 patients who are…
Phase: PHASE4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for kids with rare swelling disorder as drug trial begins
Disease control Recruiting nowThis study tests a drug called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and how it works in young bodies. Researchers will monitor side effects and measure h…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a switch to guselkumab clear stubborn psoriasis?
Disease control Recruiting nowThis study looks at how well guselkumab works for people with moderate to severe psoriasis who switch from ustekinumab (or its biosimilar) in a real-world setting. Researchers will track skin clearance using the PASI score at various time points over a year. The goal is to see if…
Sponsor: Janssen-Cilag Kft. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could a tailored IVIg dose tame a rare nerve disorder in kids?
Disease control Recruiting nowThis phase 3 trial tests two different doses of Panzyga, an intravenous immunoglobulin therapy, in children aged 2 to 17 with CIDP, a rare nerve condition causing weakness and disability. The study aims to see which dose better controls symptoms and prevents relapses, using a dis…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New study tracks Zymfentra's Real-World impact on IBD symptoms
Disease control Recruiting nowThis study follows 200 adults with Crohn's disease or ulcerative colitis who are prescribed Zymfentra as part of their regular care. Participants answer online surveys about their bowel habits for one year to see if symptoms improve. The goal is to understand how effective this m…
Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Psoriasis drug risankizumab under Real-World spotlight for quality of life boost
Disease control Recruiting nowThis study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will track changes in quality of life, including skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the drug…
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug could reverse liver scarring in MASH patients
Disease control Recruiting nowThis study tests a new drug, pegozafermin, in 1,350 adults with MASH (a type of fatty liver disease) and moderate liver scarring (stage F2 or F3). The goal is to see if the drug can improve scarring or resolve liver inflammation without making the disease worse over 52 weeks. Par…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for young lupus patients: drug trial targets kidney damage
Disease control Recruiting nowThis study tests if obinutuzumab can help teens and children with lupus nephritis, a serious kidney complication of lupus. About 40 participants aged 5 to 17 will receive either the drug or a placebo. The goal is to see if the drug improves kidney function and reduces protein in …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can reduce protein in the urine, a sign of kidney damage. About 454 adults will receive either …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New psoriasis drug ORKA-001 tested for Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New injection could stop pancreatitis from turning deadly
Disease control Recruiting nowThis study tests a single injection of a drug called RABI-767, given through a scope into the area around the pancreas, for people with predicted severe acute pancreatitis. About 36 participants will be randomly assigned to get the drug plus standard care or standard care alone. …
Phase: PHASE2 • Sponsor: Panafina, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New shot aims to free hepatitis b patients from daily pills
Disease control Recruiting nowThis Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetec…
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy aims to stop kidney damage in membranous nephropathy
Disease control Recruiting nowThis study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high pr…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can two common drugs tame rheumatoid arthritis?
Disease control Recruiting nowThis phase 2 trial tests whether adding either diosmin or rebamipide to standard rheumatoid arthritis treatment can better reduce disease activity and improve physical function. About 66 adults with active rheumatoid arthritis will be split into three groups: one receiving standa…
Phase: PHASE2 • Sponsor: Tanta University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New foot fungus film shows promise in early trial
Disease control Recruiting nowThis early-stage trial tests a new topical film called ZYG24004 for athlete's foot (tinea pedis). About 64 adults with the infection will apply the film to their feet once or twice. The main goals are to check safety, how the body processes the drug, and whether it can clear the …
Phase: PHASE1 • Sponsor: Sinomune Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Diet and exercise may tame psoriasis in kids — a trial puts it to the test
Disease control Recruiting nowThis trial tests whether a gluten-free, low-histamine diet — alone or combined with a supervised physical therapy program — can reduce skin severity and inflammation in children aged 6 to 17 with mild to moderate psoriasis. Sixty participants are randomly assigned to usual care, …
Phase: NA • Sponsor: Mahmoud Usama Mahmoud Ahmed • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Which eye drop wins the dry eye battle? a Head-to-Head test
Disease control Recruiting nowThis study tests whether Systane PRO Preservative Free eye drops are as effective as Blink Triple Care Preservative Free in relieving dry eye symptoms. Adults with mild to moderate dry eye will use one of the two drops four times a day for 30 days. Researchers will measure change…
Phase: PHASE4 • Sponsor: Gordon Schanzlin New Vision • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can insulin help heal gums? a trial puts it to the test
Disease control Recruiting nowThis trial tests whether applying insulin or hyaluronic acid gel directly into gum pockets, alongside standard deep cleaning, improves healing in people with stage III periodontitis. About 45 adults with gum disease will receive one of the two gels or cleaning alone, and research…
Phase: EARLY_PHASE1 • Sponsor: Doaa Atta Aid • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New shot aims to cure hepatitis b – early trial underway
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called AHB-137 in 84 adults with chronic hepatitis B who are already on antiviral therapy. The goal is to see if AHB-137 can clear the hepatitis B surface antigen and keep the virus under control, potentially leading to a functional c…
Phase: PHASE2 • Sponsor: AusperBio Therapeutics Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
A simple blood pressure cuff trick could shield the heart in kidney disease
Disease control Recruiting nowThis trial tests whether repeated, brief periods of reduced blood flow to the leg—created by inflating a blood pressure cuff—can improve blood pressure, heart rate, and markers of inflammation in people with chronic kidney disease. The procedure, called ischemic preconditioning, …
Phase: NA • Sponsor: Medical University of Lodz • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Experimental drug aims to protect kidneys in inflammatory diseases
Disease control Recruiting nowThis study tests an experimental drug called ADX-097 in people aged 16 and older with three kidney conditions: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The drug is given as an injection under the skin and is designed to reduce inflammation and protein leakage in t…
Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug aims to calm severe eczema without steroids
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Phase: PHASE3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug could stop knee infections after replacement
Disease control Recruiting nowThis study tests whether an investigational drug called PLG0206 can prevent infections from coming back after knee replacement surgery. About 240 adults who need a special cleaning surgery (DAIR) for an infected knee joint will receive either PLG0206 or a placebo during the proce…
Phase: PHASE2, PHASE3 • Sponsor: Peptilogics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can cyclosporine eye drops tame severe eye allergies in kids?
Disease control Recruiting nowThis trial tests whether cyclosporine 1% eye drops can help children with severe allergic eye inflammation. The main goal is to see if the drops reduce the need for rescue steroid treatments. Participants will use the eye drops daily for months and track their symptoms and steroi…
Sponsor: Semmelweis University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New shot for kids with Crohn's or colitis shows promise in phase 3 trial
Disease control Recruiting nowThis study looks at how children and teenagers with moderate to severe ulcerative colitis or Crohn's disease process a drug called vedolizumab when given as a shot under the skin. About 70 participants who already responded to vedolizumab given through a vein will receive the sho…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Lupus kidney trial aims for faster remission with drug cocktail
Disease control Recruiting nowThis study tests whether adding LUPKYNIS to standard biologic therapies (belimumab, obinutuzumab, or anifrolumab) can quickly improve kidney function in people with lupus nephritis. About 150 adults with biopsy-confirmed lupus kidney disease will receive the combination treatment…
Phase: PHASE4 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New biologic XmAb657 enters first human tests for autoimmune conditions
Disease control Recruiting nowThis early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New injection aims to tame rheumatoid arthritis
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called plamotamab in 68 adults with moderate to severe rheumatoid arthritis (RA) who haven't gotten enough relief from other treatments. The drug is given as a shot under the skin, and the main goal is to see if it's safe and …
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New daily pill shows promise for Long-Term psoriatic arthritis control
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of an oral drug called zasocitinib (TAK-279) in adults with active psoriatic arthritis, a condition causing joint pain and skin patches. About 1,182 participants who completed a one-year parent study will take either a lower…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug trial aims to slow liver disease in rare bile duct condition
Disease control Recruiting nowThis Phase 3 study tests whether the drug elafibranor can slow liver damage in adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts. About 350 participants will receive either elafibranor or a placebo daily for several years. The main goal is…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug MER511 enters first human trial for Graves' disease
Disease control Recruiting nowThis early-stage trial tests a new biologic drug called MER511 in 100 adults with Graves' disease. The main goal is to check safety and side effects, and to see how the body handles the drug when given by IV or injection. Participants must be on stable thyroid medication. The stu…
Phase: PHASE1 • Sponsor: Merida Biosciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo aims to tame hepatitis b virus
Disease control Recruiting nowThis study tests two drugs, VIR-2218 and peginterferon, in 50 adults with mild chronic hepatitis B. The goal is to lower the virus level in the blood and improve the body's immune response. Participants receive injections for 6 months and are followed for over 2 years, including …
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug aims to slow kidney damage in diabetes and rare diseases
Disease control Recruiting nowThis study tests an experimental drug called WAL0921 in 96 adults with kidney diseases that cause protein in the urine, including diabetic nephropathy and several rare conditions. Participants receive either the drug or a placebo as an IV infusion every two weeks for 14 weeks, th…
Phase: PHASE2 • Sponsor: Walden Biosciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for kidney patients: experimental drug takes on standard therapy
Disease control Recruiting nowThis study tests a new drug, povetacicept, against a standard treatment (calcineurin inhibitor) in 176 adults with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the new drug can put the disease into remission more safely a…
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Arthritis drug xeljanz XR under Real-World watch in korea
Disease control Recruiting nowThis study tracks the safety and effectiveness of the arthritis drug Xeljanz XR in about 200 adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Participants take the drug as prescribed by their doctor, and researchers record any s…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New study tracks xeljanz safety in kids with arthritis
Disease control Recruiting nowThis study looks at the safety and effectiveness of the drug Xeljanz in children aged 2 to 17 with active juvenile idiopathic arthritis or juvenile psoriatic arthritis. It is an observational study in Korean clinics, meaning doctors prescribe the drug as usual and researchers mon…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New shot could tame stubborn hives when pills fail
Disease control Recruiting nowThis study tests an injection called JYB1904 in 180 adults with chronic spontaneous urticaria (hives and itching lasting over 6 weeks) that isn't well controlled by standard antihistamines. Participants receive either the drug or a placebo every 12 weeks for 48 weeks. The main go…
Phase: PHASE3 • Sponsor: Jemincare • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Which biologic is best for nasal polyps? new study aims to find out
Disease control Recruiting nowThis study will compare three FDA-approved biologic drugs (dupilumab, omalizumab, and mepolizumab) in 504 adults with chronic sinusitis and nasal polyps. The goal is to see which drug works best for different patients and whether simple tests can predict who will improve the most…
Phase: PHASE4 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a poop pill save lives? new trial targets superbug lung infections in ICU patients
Disease control Recruiting nowThis study tests whether fecal microbiota transplantation (FMT) — transferring healthy donor stool into the gut — can lower the risk of death in ventilated ICU patients with multidrug-resistant lung infections. The idea is that restoring gut bacteria may help fight lung infection…
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on lupus and more
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New trial aims to solve JIA treatment puzzle after first drug fails
Disease control Recruiting nowThis study is for children aged 2 to 17 with polyarticular juvenile idiopathic arthritis (JIA) whose first TNF inhibitor medication did not work well enough. It compares three different non-TNFi drugs (abatacept, tocilizumab, tofacitinib) against a second TNF inhibitor to see whi…
Phase: PHASE3 • Sponsor: Duke University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a new drug tame fatty liver disease? early trial aims to find out
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called INI-822 to see if it is safe and tolerable. It involves healthy volunteers and people with MASH, a type of fatty liver disease. The study will give different doses of the drug or a placebo to see how the body handles i…
Phase: PHASE1 • Sponsor: Inipharm Australia Pty Ltd • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a gentler gum treatment change the chemical signature of periodontitis?
Disease control Recruiting nowThis trial compares two non-surgical approaches for treating periodontitis: a minimally invasive technique (MINST) and a quadrant-by-quadrant deep cleaning (Q-SI). Researchers will measure changes in gum pocket depth and analyze the chemical makeup of fluid from the gums before a…
Phase: NA • Sponsor: University of Catania • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can Weight-Loss surgery beat drugs for advanced liver damage?
Disease control Recruiting nowThis trial compares two approaches for treating advanced metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. About 120 adults with MASH and liver fibrosis will be randomly assigned to either metabolic surgery (gastric bypass or sl…
Phase: PHASE4 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Which thumb arthritis surgery works best? a Head-to-Head trial aims to find out
Disease control Recruiting nowThis trial compares three common surgical procedures for thumb basal joint arthritis: trapeziectomy with ligament reconstruction, trapeziectomy with suture suspensionplasty, and arthroscopic trapeziectomy alone. The goal is to see which technique best restores grip and pinch stre…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can an ancient herbal mix tame psoriasis flares?
Disease control Recruiting nowThis trial tests whether a traditional Chinese herbal formula called SDD can safely reduce the severity of plaque psoriasis, a common inflammatory skin condition. Adults with mild-to-moderate psoriasis will receive either SDD or a placebo daily for 12 weeks. Researchers will meas…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Ancient herbal mix put to the test against childhood eczema
Disease control Recruiting nowThis trial tests whether a modified version of the traditional Chinese herbal formula Qing-Ying Decoction can reduce eczema severity in children aged 4 to 17. Participants receive either the herbal granules or a placebo for 12 weeks, followed by 4 weeks of monitoring. Researchers…
Phase: PHASE2, PHASE3 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Blood-Derived shot may mend Worn-Out knees
Disease control Recruiting nowThis trial tests whether injections of platelet-rich plasma (PRP) — a concentrate from a person's own blood — can repair knee osteoarthritis and injuries to cartilage, meniscus, and ligaments. Researchers will compare PRP against standard hyaluronic acid injections in 300 adults …
Phase: NA • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a pill beat dandruff? oral antifungal takes on stubborn scalp condition
Disease control Recruiting nowThis trial tests whether oral itraconazole, taken as a pulse therapy over six months, works better than a standard ketoconazole shampoo for moderate to severe scalp seborrheic dermatitis. Eighty participants aged 14 to 70 will be randomly assigned to one of the two treatments. Re…
Phase: EARLY_PHASE1 • Sponsor: Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common antibiotic beat MRSA in kids? a trial puts TMP-SMX to the test
Disease control Recruiting nowThis trial compares two oral antibiotics—trimethoprim-sulfamethoxazole (TMP-SMX) and clindamycin—to see which works better for children with invasive MRSA infections, such as bone, joint, or deep tissue infections. About 100 children aged 60 days to 18 years will take one of the …
Phase: PHASE4 • Sponsor: Indiana University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a string swallowed in a pill replace endoscopy for EoE?
Diagnosis Recruiting nowThis study tests whether a simple esophageal string test (EST) can diagnose eosinophilic esophagitis (EoE) in people who have trouble swallowing. Participants swallow a capsule with a nylon string that collects fluid from the esophagus, which is then analyzed. The results will be…
Phase: NA • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Diagnosis
Last updated Aug 18, 2026 00:00 UTC
-
Blood test could outshine ultrasound in liver cancer screening
Diagnosis Recruiting nowThis phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
AI stethoscope aims to spot hidden heart and lung problems in children
Diagnosis Recruiting nowThis trial is developing an AI-powered device that listens to children's heart, breath, and bowel sounds to identify signs of common diseases like congenital heart disease, bronchopneumonia, and abdominal issues. It will involve 30,000 children aged 0-18, some with these conditio…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Ultrasound and EMG may tell inflammatory from mechanical shoulder issues
Diagnosis Recruiting nowThis study compares muscle thickness around the shoulder blade in people with early ankylosing spondylitis (an inflammatory condition) versus those with mechanical shoulder blade movement problems. Researchers use ultrasound and electromyography (EMG) to see if they can tell the …
Sponsor: Tanta University • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New imaging tool could make mouth biopsies more accurate
Diagnosis Recruiting nowThis study tests a new imaging device called the Active Biopsy Guidance System to help doctors decide when and where to take tissue samples (biopsies) from mouth lesions. About 90 adults with suspicious mouth spots or a history of oral cancer will participate. The goal is to see …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
A Finger-Prick could change the fight against hepatitis c
Diagnosis Recruiting nowThis large Australian study is testing whether offering a finger-stick point-of-care test for hepatitis C can increase diagnosis and treatment rates. Adults at risk for hepatitis C will be offered the rapid test at services they already use. Those who test positive for the virus …
Sponsor: Kirby Institute • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
A simple finger prick could transform hepatitis c care
Diagnosis Recruiting nowThis large Australian study is testing whether offering finger-stick point-of-care testing for hepatitis C in community settings—like drug treatment clinics, homeless shelters, and prisons—can increase the number of people diagnosed and linked to treatment. The study will include…
Sponsor: Kirby Institute • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
A quick test for septic arthritis in kids — could it save joints?
Diagnosis Recruiting nowThis study tests whether proteins in joint fluid, such as alpha-defensin, can quickly and accurately detect bacterial joint infections (septic arthritis) in children. Currently, doctors rely on cultures that take days, forcing tough decisions about emergency surgery. The trial co…
Phase: NA • Sponsor: Hospital for Special Surgery, New York • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Grape powder may help aging immune systems — a trial puts it to the test
Prevention Recruiting nowThis study tests whether daily consumption of freeze-dried grape powder can improve immune function and reduce inflammation in healthy adults aged 50 to 75. Participants will drink a grape powder beverage or a placebo for four weeks each, while avoiding grapes and other polypheno…
Phase: NA • Sponsor: University of Connecticut • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a single shot stop c. diff from returning?
Prevention Recruiting nowThis study tests a new drug called AZD5148 to see if it can prevent repeat C. diff infections in adults. About 230 people will get either the drug or a placebo as a single injection. The goal is to stop the infection from coming back after standard treatment.
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Could a single friendly gut bacterium prevent recurrent c. diff?
Prevention Recruiting nowThis study tests EXL01, a single strain of a beneficial gut bacterium (Faecalibacterium prausnitzii), to see if it can prevent repeat Clostridioides difficile infections in people at high risk. About 56 adults who have had at least two C. diff episodes will take EXL01 or a placeb…
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
Can coaching clinics curb HIV? a new strategy puts it to the test
Prevention Recruiting nowThis study tests whether a 'practice coaching' program can help opioid treatment clinics offer more HIV and hepatitis C testing to their patients. Clinics are randomly assigned to receive either coaching focused on HIV testing, coaching that adds hepatitis C testing, or just info…
Phase: NA • Sponsor: Columbia University • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Flu vaccine showdown: which shot protects seniors best?
Prevention Recruiting nowThis study compares two flu vaccines—Fluad and Fluzone High-Dose—in adults aged 65 and older to see which is more effective at preventing lab-confirmed flu and related complications like pneumonia or heart issues. Researchers will look at health records from over a million senior…
Sponsor: Kaiser Permanente • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Could removing the gallbladder stop mystery pancreatitis attacks?
Prevention Recruiting nowThis trial tests whether removing the gallbladder with keyhole surgery can prevent repeat episodes of acute pancreatitis in people whose cause remains unknown after thorough testing. Half the participants will have the surgery, while the other half will receive watchful waiting. …
Phase: NA • Sponsor: M.G. Besselink • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
Chilled water may curb pancreatitis risk after Bile-Duct procedure
Prevention Recruiting nowThis trial tests whether rinsing the bile-duct opening with ice-cold water, on top of standard anti-inflammatory medication, can lower the chance of pancreatitis after an ERCP procedure. About 462 adults who need an ERCP will receive either the usual NSAID pill alone or the NSAID…
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Prevention
Last updated Aug 01, 2026 00:00 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New allergy spray trial aims to help teens breathe easier
Symptom relief Recruiting nowThis study tests if Dymista nasal spray safely eases allergy symptoms like sneezing, stuffy nose, and itchy eyes in Chinese teenagers aged 12 to 17. About 100 participants will use the spray twice daily for two weeks. The goal is to see if symptoms improve, not to cure allergies.
Phase: PHASE4 • Sponsor: Viatris Inc. • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…
Phase: PHASE1 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New hope for painful skin condition: experimental drug LAD328 enters phase 2 trial
Symptom relief Recruiting nowThis study tests whether the experimental drug LAD328 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 50 adults with moderate-to-severe disease will receive either LAD328 or a placebo. The main goal is to see if the drug lead…
Phase: PHASE2 • Sponsor: Almirall, S.A. • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Heel pain breakthrough? study tests nerve combo treatment
Symptom relief Recruiting nowThis study looks at whether treating an extra nerve in the foot can improve pain relief for people with long-term heel pain. About 48 adults will receive a standard nerve treatment, with half also getting treatment on a second nerve. Researchers will measure pain and foot functio…
Sponsor: Diskapi Teaching and Research Hospital • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Can a laser beam ease pain after Root-End surgery?
Symptom relief Recruiting nowThis trial tests whether photobiomodulation (PBM), a type of low-level laser therapy, can reduce pain and improve healing after endodontic microsurgery—a procedure to treat infections at the tip of a tooth root. About 90 adults needing this surgery will receive either real PBM or…
Phase: NA • Sponsor: The University of Texas Health Science Center, Houston • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New injection could tame seasonal allergy symptoms for those failed by standard treatments
Symptom relief Recruiting nowThis Phase 3 trial tests an investigational injection called SHR-1819 in adults aged 18 to 75 with seasonal allergic rhinitis (hay fever) who haven't gotten enough relief from standard treatments like nasal sprays or antihistamines. The study compares the drug to a placebo to see…
Phase: PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Could your own fat ease shoulder arthritis pain?
Symptom relief Recruiting nowThis study compares injections of a patient's own processed fat tissue (MFAT) against standard steroid shots for shoulder osteoarthritis. Researchers will track pain, function, and quality of life in 48 adults aged 25-75. The goal is to see if the fat injection provides better or…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New weekly shot could shed pounds and ease knee pain
Symptom relief Recruiting nowThis Phase 3 study tests a once-weekly injection called NNC0487-0111 in 400 adults who are overweight or obese and have knee osteoarthritis. The goal is to see if it helps with weight loss and reduces knee pain compared to a placebo. Participants receive either the active drug or…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New pill could ease severe eczema itch and rash
Symptom relief Recruiting nowThis study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Can a meditation practice curb Post-Surgery pain and opioid use?
Symptom relief Recruiting nowThis trial tests whether a brief course of savoring meditation—a practice that generates positive emotions—can reduce pain and improve reward system function in people undergoing knee replacement for osteoarthritis. Half of the 150 participants will receive this meditation traini…
Phase: NA • Sponsor: University of Virginia • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New eyeglass attachment could soothe dry eyes in just two hours
Symptom relief Recruiting nowThis study tests a disposable silicone device that clips onto eyeglasses to trap moisture around the eyes. Thirty-five adults with mild to moderate dry eye will wear it for two hours. Researchers will measure tear film stability, tear volume, and symptom changes before and after …
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Could a common heartburn drug shield lung cancer patients from radiation side effects?
Symptom relief Recruiting nowThis phase II trial tests whether esomeprazole, a common acid-reducing drug, can lower the chance of severe esophagitis (inflammation of the food pipe) in people with stage III non-small cell lung cancer receiving radiation therapy. Participants take 40 mg of esomeprazole daily d…
Phase: PHASE2 • Sponsor: Rush University Medical Center • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New cream targets itch in eczema patients
Symptom relief Recruiting nowThis study tests a cream called roflumilast 0.15% for itching in people with mild to moderate atopic dermatitis (eczema). About 40 participants aged 12 and older will apply the cream once daily for 4 weeks. Researchers will track how patients describe their itch and other skin se…
Phase: PHASE4 • Sponsor: Integrative Skin Science and Research • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New knee pain drug enters human testing
Symptom relief Recruiting nowThis early-stage study tests a drug called CX-011 for moderate to severe knee osteoarthritis pain. About 72 adults aged 18-75 with knee osteoarthritis will receive the drug via injection into the knee joint. The main goals are to check safety and tolerability, and to see if it re…
Phase: PHASE1, PHASE2 • Sponsor: CarthroniX, Inc. • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Gum surgery showdown: which stitch heals best?
Symptom relief Recruiting nowThis study compares two types of stitches (NOVOSYN quick and MONOSYN quick) used in gum surgery to see if they heal equally well. About 84 adults having gum surgery will be randomly assigned one of the two stitches. The main goal is to check early healing signs like skin regrowth…
Phase: NA • Sponsor: Aesculap AG • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Robot knee surgery showdown: can skipping the scan still deliver?
Symptom relief Recruiting nowThis study compares two robot-assisted knee replacement methods for people with severe knee arthritis. One method uses a CT scan to plan the surgery (image-based), while the other uses a simpler approach without a scan (imageless). The goal is to see if the imageless method works…
Phase: NA • Sponsor: Medical University of Warsaw • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 198 participants will receive either BBT001 or a placebo, wit…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Blocking knee blood vessels may offer new pain relief for severe osteoarthritis
Symptom relief Recruiting nowThis trial tests whether genicular artery embolization (GAE), a procedure that blocks certain blood vessels in the knee, can reduce persistent pain in people with severe knee osteoarthritis who haven't found relief from conservative treatments and may not be candidates for surger…
Phase: NA • Sponsor: King Abdullah International Medical Research Center • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can education boost exercise compliance for chronic pain sufferers?
Symptom relief Recruiting nowThis trial tests whether adding a structured patient education program to standard physical therapy helps people with chronic low back pain, knee osteoarthritis, or shoulder pain stick to their prescribed home exercises. Participants will be randomly assigned to receive either st…
Phase: NA • Sponsor: Imam Abdulrahman Bin Faisal University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Could a Cardamom-Bacteria spray soothe your eczema?
Symptom relief Recruiting nowThis study tests if a spray made from ground cardamom seeds and a harmless skin bacteria (Roseomonas mucosa) can improve eczema symptoms in people aged 2 and older. Participants apply the spray 2-3 times a week for 14 weeks and are monitored remotely for about 7 months. Half rece…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can a digestive enzyme combo beat standard painkillers for root canal pain?
Symptom relief Recruiting nowThis trial tests three pain-relief approaches after a single-visit root canal in people with symptomatic irreversible pulpitis, a painful tooth condition. Participants receive either acetaminophen, an NSAID, or a combination of trypsin-chymotrypsin with acetaminophen for three da…
Phase: EARLY_PHASE1 • Sponsor: Dow University of Health Sciences • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Could an antidepressant curb opioid use after knee surgery?
Symptom relief Recruiting nowThis study tests whether the antidepressant duloxetine can help reduce opioid painkiller use after knee replacement surgery. About 150 adults with knee osteoarthritis will receive either duloxetine or a placebo before and after surgery. The goal is to see if duloxetine lowers opi…
Phase: PHASE4 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New lung therapy may help ventilated patients recover faster
Symptom relief Recruiting nowThis study tests whether adding a special breathing treatment called intrapulmonary percussive ventilation (IPV) to standard care helps patients with pneumonia who are on a breathing machine. About 96 adults will be randomly assigned to receive either standard therapy alone or st…
Phase: NA • Sponsor: Zhongnan Hospital • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Experimental antibodies aim to block cat allergy eye itch
Symptom relief Recruiting nowThis study tests whether two experimental antibodies, given alone or together, can reduce eye allergy symptoms caused by cat dander. About 570 adults and children aged 8 and older with confirmed cat allergy will receive either the antibodies or a placebo. The main goal is to see …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can cutting carbs curb knee pain? a diet trial puts it to the test
Symptom relief Recruiting nowThis study investigates whether a low-carbohydrate diet can reduce pain and improve quality of life in adults with knee osteoarthritis, compared to a standard USDA-recommended diet. Participants will follow a 6-week diet plan with all meals provided, and researchers will measure …
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Ancient herbs, modern relief? a patch takes on heel pain
Symptom relief Recruiting nowThis trial tests whether a new patch made from traditional Chinese herbs (CDAM) can reduce pain and improve function in people with plantar fasciitis, a common cause of heel pain. About 120 adults with heel pain lasting over six weeks will receive either the herbal patch or a sta…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New pill aims to shorten COPD Flare-Ups from common cold
Symptom relief Recruiting nowThis study tests an oral drug called vapendavir in 180 adults with COPD who catch a rhinovirus (common cold). The goal is to see if it can reduce the severity and length of breathing symptoms compared to a placebo. Participants are randomly assigned to one of two doses or a place…
Phase: PHASE2 • Sponsor: Altesa Biosciences, Inc. • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New eye drop BUFY01 takes on SVS20 in dry eye showdown
Symptom relief Recruiting nowThis study tests whether a new eye drop, BUFY01, works as well as an existing one, SVS20, for people with dry eye disease. About 80 participants will use one of the two drops daily for three months. Researchers will check eye health and ask about symptoms to see if the treatments…
Phase: NA • Sponsor: TRB Chemedica International SA • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a magnetic chair ease bowel leakage after J-Pouch surgery?
Symptom relief Recruiting nowThis study tests whether a special chair that delivers high-intensity electromagnetic stimulation can improve bowel leakage (fecal incontinence) and quality of life in people who have a J-pouch after surgery for ulcerative colitis. Participants will sit on the Emsella chair for 2…
Phase: NA • Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New injection aims to ease arthritis pain in joints
Symptom relief Recruiting nowThis early-stage study tests a new drug called F8IL10, given as an injection directly into the joint, for people with rheumatoid arthritis. The main goal is to find a safe dose and see if it helps reduce joint pain and swelling. About 42 adults with active arthritis in a knee, an…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
Symptom relief Recruiting nowThis study tests whether adding lymphatic pump osteopathic manipulative therapy (OMT) to standard care helps older adults recover faster from respiratory illnesses like bronchitis, sinusitis, or pneumonia. Participants aged 65 to 100 with a new respiratory diagnosis will receive …
Phase: NA • Sponsor: Geisinger Clinic • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can sound waves outperform needles for Jumper's knee?
Symptom relief Recruiting nowThis trial compares two non-surgical treatments for jumper's knee, a common overuse injury causing knee pain. Half the participants will receive extracorporeal shockwave therapy, which uses sound waves to stimulate healing, while the other half will receive dry needling, which in…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Freeze or zap? new trial tests Drug-Free pain relief for stubborn knee arthritis
Symptom relief Recruiting nowThis study compares two minimally invasive procedures—cryoneurolysis (freezing nerves) and radiofrequency (using electric pulses)—to relieve knee pain in adults with osteoarthritis who haven't responded to standard treatments like painkillers or physical therapy. Sixty participan…
Phase: NA • Sponsor: Tanta University • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Could adding cupping to acupuncture double shoulder pain relief?
Symptom relief Recruiting nowThis study tests whether combining electroacupuncture with vacuum cupping therapy works better than electroacupuncture alone for shoulder tendinitis. Fifty-four adults with shoulder pain and stiffness will receive either electroacupuncture alone or electroacupuncture plus cupping…
Phase: NA • Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can an online course ease fatigue in autoimmune disease?
Symptom relief Recruiting nowThis study tests an online wellness course that teaches diet, exercise, stress reduction, and self-care to people with rheumatoid arthritis, lupus, Sjogren's syndrome, and similar conditions. Researchers want to see if the program reduces fatigue and improves quality of life. Abo…
Phase: NA • Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a daily probiotic soothe colicky babies and calm eczema?
Symptom relief Recruiting nowThis trial tests whether giving formula-fed infants under 5 months a daily probiotic (Bifidobacterium bifidum) can reduce crying time by at least half in babies with colic, and also improve eczema symptoms. Over 8 weeks, half the babies receive the probiotic drops and half receiv…
Phase: NA • Sponsor: University of Roma La Sapienza • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a meditation app soothe teen eczema?
Symptom relief Recruiting nowThis trial tests whether regular use of a digital mindfulness meditation app can help adolescents aged 12-17 with moderate to severe atopic dermatitis (eczema) improve disease control and quality of life. Participants will use the app for 10-15 minutes, 3-4 times a week, while a …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Which nerve drug wins the battle against Post-Surgical knee pain?
Symptom relief Recruiting nowThis trial asks whether mirogabalin or pregabalin provides better pain relief after total knee replacement surgery. Adults aged 50-85 with knee osteoarthritis will take one of the two drugs for two weeks after surgery. Researchers will measure pain scores, morphine use, and knee …
Phase: NA • Sponsor: Thammasat University Hospital • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Can a simple supplement soothe Radiation-Damaged rectums?
Symptom relief Recruiting nowThis phase 2 trial tests whether a dietary supplement called tributyrin can reduce rectal bleeding in people who developed chronic radiation proctitis after pelvic radiotherapy. Participants take the supplement orally for 12 weeks, and researchers will measure changes in bleeding…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Could fixing sleep before knee surgery cut Long-Term pain?
Symptom relief Recruiting nowThis study tests whether improving sleep before total knee replacement surgery can reduce pain after the operation. Adults aged 60 and older with knee osteoarthritis and sleep difficulties will receive either cognitive-behavioral therapy for insomnia, bright light therapy, or a c…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Can specialized exercise ease knee arthritis disability?
Symptom relief Recruiting nowThis trial tests whether eccentric strengthening exercises or low-load blood flow restriction training can improve muscle function, strength, and daily mobility in people with knee osteoarthritis. Participants aged 40 to 70 with mild to moderate knee arthritis will follow a four-…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
One-Shot gene therapy could ease knee arthritis pain for years
Symptom relief Recruiting nowThis Phase 2 trial tests a single injection of a gene therapy called PCRX-201 in 135 adults aged 45–80 with painful knee osteoarthritis. Participants receive one of two doses or a placebo, then are monitored for safety and pain relief over 5 years. The goal is to see if the injec…
Phase: PHASE2 • Sponsor: Pacira Pharmaceuticals, Inc • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Tiny tailbone device may calm urgent bathroom trips for colitis patients
Symptom relief Recruiting nowThis study tests a small device placed under the skin near the tailbone that sends mild signals to a nerve, aiming to reduce sudden bowel urgency in people with ulcerative colitis. About 137 adults with the condition will take part. The device is implanted in a same-day procedure…
Phase: NA • Sponsor: Boomerang Medical • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
Symptom relief Recruiting nowThis pilot study tests a care model called Patient Priorities Care (PPC) for older African Americans with heart disease plus other chronic conditions like diabetes or COPD. The approach shifts focus from treating each disease separately to aligning care with what matters most to …
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Can shock waves or electrotherapy ease Menopause-Linked tennis elbow?
Symptom relief Recruiting nowThis trial tests whether a combination of electrotherapy (low-level laser and interferential current) or shock wave therapy, alongside stretching and strengthening exercises, can reduce pain and improve grip strength in menopausal women with tennis elbow. The study includes 45 wo…
Phase: NA • Sponsor: October 6 University • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New daily pill could ease knee pain and help weight loss in obesity
Symptom relief Recruiting nowThis study tests a once-daily pill called orforglipron in 800 adults with obesity or overweight who also have painful knee osteoarthritis. The goal is to see if the drug reduces knee pain and improves physical function over about 74 weeks. Participants will be randomly assigned t…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Can a simple spray soothe Post-Surgery throat pain?
Symptom relief Recruiting nowThis trial tests whether a benzydamine throat spray, an anti-inflammatory pain reliever, can reduce sore throat after surgery that uses a breathing tube. About 106 women undergoing gynecological surgery will be randomly assigned to receive the spray or usual care. The study will …
Phase: EARLY_PHASE1 • Sponsor: KK Women's and Children's Hospital • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New shot aims to ease depression and anxiety in cancer and chronic disease patients
Symptom relief Recruiting nowThis study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…
Phase: PHASE2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New weekly shot aims to ease arthritic knee pain and shed pounds
Symptom relief Recruiting nowThis Phase 3 study tests a once-weekly injection called eloralintide in 900 adults with osteoarthritis of the knee who are also overweight or obese. The goal is to see if it reduces knee pain and helps with weight loss compared to a placebo. Participants will be in the study for …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Can coconut oil calm acne without irritating sensitive skin?
Symptom relief Recruiting nowThis study tests a 4-week skincare routine made with coconut oil to see if it safely and effectively manages mild to moderate acne in people with sensitive skin. Participants will use a cleanser, toner, serum, and day cream, with skin assessments at the start and end of the trial…
Phase: NA • Sponsor: USMARI Research & Innovation Centre • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Phone app aims to speed recovery after hip, knee, and spine surgery
Symptom relief Recruiting nowThis study tests whether a mobile app can help patients do simple in-bed exercises after orthopedic surgery for spine, hip, or knee problems. About 100 participants will use the app or receive usual care. Researchers will measure how well patients recover their ability to move an…
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
New devices aim to soothe sore throats without drugs
Symptom relief Recruiting nowThis study will test four medical devices (HMG, PHN, PHR, TUR) in 160 adults with sore throat from acute pharyngitis or viral tonsillitis. The goal is to see if they are safe and help reduce symptoms like pain when swallowing. Participants will use the device for up to 7 days and…
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Mouthwash may stop cancer Drug's painful side effect
Symptom relief Recruiting nowThis study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Could a common cholesterol drug ease pancreatitis pain?
Symptom relief Recruiting nowThis pilot study tests whether simvastatin, a common cholesterol medication, can improve quality of life in adults with recurrent acute or chronic pancreatitis. Researchers will enroll 90 participants to check if the drug is feasible and acceptable. The goal is to see if it helps…
Phase: EARLY_PHASE1 • Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Can a steroid shot make thyroid surgery safer?
Symptom relief Recruiting nowThis trial tests whether taking a short course of dexamethasone before surgery can reduce inflammation in the thyroid gland, making the operation easier for the surgeon. It includes adults with Graves' disease or Hashimoto's disease who are scheduled for a total thyroidectomy. Pa…
Phase: PHASE4 • Sponsor: Indiana University • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Shock wave or splint? new study tests best treatment for trigger finger
Symptom relief Recruiting nowThis study compares two common treatments for trigger finger: shock wave therapy and a finger splint. Researchers will enroll 54 adults with early-stage trigger finger to see which approach better reduces pain and improves hand function. The goal is to find out if shock wave ther…
Phase: NA • Sponsor: Hacettepe University • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Common nausea pill may tame immunotherapy's harsh side effects in liver cancer
Symptom relief Recruiting nowThis study tests whether ondansetron, a drug typically used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron alongside their standard cancer treatment. The goal is to see if thi…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
New gel injection aims to soothe sore tendons
Symptom relief Recruiting nowThis study is testing a gel called OSTENIL TENDON to see if it safely reduces pain and improves movement in people with tendon problems. Researchers will enroll 84 adults with one of four types of tendinopathy. The main goal is to measure pain changes three months after treatment…
Sponsor: TRB Chemedica AG • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Sleep hormone melatonin put to the test for IBD patients with poor sleep
Symptom relief Recruiting nowThis phase 4 trial tests whether taking a 2 mg prolonged-release melatonin tablet before bed can improve sleep quality in adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) whose disease is in remission. Participants must have poor sleep (PSQI score >5…
Phase: PHASE4 • Sponsor: Mahidol University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could a mix of moves and mindset ease frozen shoulder?
Symptom relief Recruiting nowThis study tests whether a combination of special joint mobilizations, pain education, and core exercises can reduce pain and improve shoulder function in people with frozen shoulder. Thirty-six adults with the condition will be randomly assigned to either this new program or sta…
Phase: NA • Sponsor: Yeditepe University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Toy nebulizers or distraction cards: which eases Kids' fear best?
Symptom relief Recruiting nowThis study tests two simple ways to reduce fear in children aged 3-6 who need breathing treatments (nebulization) for conditions like asthma. One group uses a toy-shaped nebulizer, another uses colorful distraction cards with games, and a third group gets standard care. Researche…
Phase: NA • Sponsor: University of Baghdad • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Could a common antioxidant shield cancer patients from painful mouth sores?
Symptom relief Recruiting nowThis trial tests whether alpha-lipoic acid, a powerful antioxidant, can prevent oral mucositis—painful mouth sores—caused by the chemotherapy drug 5-fluorouracil in colorectal cancer patients. Half of the 50 participants will take alpha-lipoic acid twice daily for six months, whi…
Phase: PHASE2, PHASE3 • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Can a new drug called ZP9830 calm psoriasis Flare-Ups?
Symptom relief Recruiting nowThis trial investigates whether an experimental drug, ZP9830, can safely improve symptoms of plaque psoriasis when taken over 8 weeks. The study includes adults with stable plaque psoriasis who have at least two visible plaques. Researchers will monitor side effects, measure how …
Phase: PHASE1 • Sponsor: Zealand Pharma • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Scientists dig into skin bugs to unlock eczema secrets
Knowledge-focused Recruiting nowThis study looks at the tiny organisms living on our skin—like bacteria and fungi—and how they might differ in people with eczema (atopic dermatitis). Researchers will collect skin samples from healthy volunteers and patients aged 2 to 40 with moderate to severe eczema, as well a…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can we spot cancer before it starts? a massive study aims to find out
Knowledge-focused Recruiting nowThis study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
HIV study aims to unlock mystery of Post-Treatment immune Flare-Ups
Knowledge-focused Recruiting nowThis study looks at why some people with HIV develop Immune Reconstitution Inflammatory Syndrome (IRIS) after starting HIV medications. Researchers will use PET scans and lymph node biopsies to track inflammation and immune recovery in 300 adults. The goal is to better understand…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
500 patients enrolled in Largest-Ever study of brain tapeworm outcomes
Knowledge-focused Recruiting nowThis study follows 500 people with neurocysticercosis, a brain infection caused by the pork tapeworm. Participants receive standard antiparasitic drugs and anti-inflammatories. Researchers will track their health over many years to understand what factors lead to better or worse …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
500 patients to help unlock secrets of knee recovery
Knowledge-focused Recruiting nowThis study will follow 500 people with knee injuries or knee osteoarthritis who receive standard care at a hospital in China. Researchers will collect medical history, imaging, and function tests at the start and then again at 6, 12, and 24 months. The goal is to better understan…
Sponsor: Ningbo No.2 Hospital • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek clues to why some get sick from parasitic worms
Knowledge-focused Recruiting nowThis study looks at how people's immune systems react to infections from parasitic worms, which can cause serious health problems like swelling, blindness, or heart disease. Researchers will evaluate and treat up to 500 participants aged 3 to 100 using standard medical tests and …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can your genes predict eye damage from a common arthritis drug?
Knowledge-focused Recruiting nowThis study looks at whether certain genes make some people more likely to develop eye damage from the drug Plaquenil, which is used for autoimmune diseases like lupus and rheumatoid arthritis. Researchers will compare people who have had eye damage from Plaquenil with those who h…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists hunt for protein clues to Pneumonia's hidden causes
Knowledge-focused Recruiting nowThis study looks at proteins in lung fluid from 750 people with pneumonia to find biomarkers that could reveal what's causing the lung inflammation. Participants undergo a standard bronchoscopy with lung washings, plus a blood draw. The goal is to better understand different type…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive heart study seeks 5,000 volunteers to uncover hidden risks
Knowledge-focused Recruiting nowThis study aims to learn more about heart and blood vessel diseases by observing people who have them or are at risk. Researchers will collect samples and perform tests like imaging and stress tests on up to 5,000 participants, including healthy volunteers and relatives of affect…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive study aims to unlock mysteries of rare blood vessel disease
Knowledge-focused Recruiting nowThis study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive liver study seeks 8,000 volunteers to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
New study probes immune system in rare disease patients
Knowledge-focused Recruiting nowThis study looks at how common certain antibodies and inflammatory markers are in people with chronic granulomatous disease (CGD). Researchers will measure levels of adenovirus-fighting antibodies and inflammatory cytokines in blood samples from 60 adults and children with CGD. T…
Sponsor: Ensoma • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Gene hunt in peru: could ancestry hold key to autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek clues to fungal infections in immune system study
Knowledge-focused Recruiting nowThis study aims to understand why some people are more prone to fungal infections, especially from Candida yeast. Researchers will collect blood, saliva, urine, and tissue samples from people with immune disorders, their family members, and healthy volunteers. No treatment is giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Ultrasound measurements may predict who benefits from knee pain block
Knowledge-focused Recruiting nowThis study looks at whether ultrasound measurements of thigh muscle and fat can predict how well patients with knee osteoarthritis respond to a genicular nerve block. Researchers will measure muscle thickness and fat under the skin before the procedure and check pain levels one m…
Sponsor: Gaziosmanpasa Research and Education Hospital • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists launch deep dive into rare liver disease PSC
Knowledge-focused Recruiting nowThis study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatmen…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Blood cell harvest could fuel future immune disease cures
Knowledge-focused Recruiting nowThis study collects blood stem cells and immune cells from healthy volunteers and patients with primary immune deficiencies or blood disorders. The cells are used in the lab to develop new gene and cell therapies. Up to 850 adults aged 18-70 will participate. The goal is to advan…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
AI aims to end Skin-Tone bias in dermatology
Knowledge-focused Recruiting nowThis study is testing whether artificial intelligence can accurately classify skin pigment, sun sensitivity (phototype), and sun damage from standard photos of the arm. Researchers will enroll 1,500 adults from diverse backgrounds, combining objective color measurements, expert a…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Gut fungi linked to lung trouble in HIV patients
Knowledge-focused Recruiting nowThis study looks at whether fungi moving from the gut into the blood can cause inflammation and worsen lung function in people with HIV. Researchers will measure a fungal marker called BDG in blood and urine, and track lung health over three years. The goal is to better understan…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Scientists launch massive microbiome collection to unlock secrets of the Body's tiny tenants
Knowledge-focused Recruiting nowThis study is creating a large collection of microbiome samples—like stool, saliva, and skin swabs—from 600 people of all ages, including healthy volunteers and those with various illnesses. The goal is to build a resource for future research on how the microbiome affects health …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New blood test could spot pancreatic cancer sooner
Knowledge-focused Recruiting nowThis study aims to create a simple, minimally invasive test to find pancreatic cancer at an early stage and track how well treatment is working. Researchers will study 700 people with pancreatic cancer, pancreatitis, or pancreatic cysts. The goal is to identify biological markers…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can discarded bone reveal the secrets to stronger bones?
Knowledge-focused Recruiting nowThis study aims to understand why bones weaken with age, leading to conditions like osteoporosis and osteoarthritis. Researchers will collect bone waste and blood samples from 2,000 people undergoing orthopedic surgery, including those with and without bone disease. By analyzing …
Sponsor: Relation Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Shoulder replacement study peers inside muscles years later
Knowledge-focused Recruiting nowThis study looks at how the rotator cuff muscles are doing one and two years after total shoulder replacement surgery. Researchers will use EMG and CT scans to check for nerve damage or tears in the muscles. About 30 adults who had shoulder replacement for osteoarthritis will tak…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Quick fingerprick test could curb infection spread in rural west virginia
Knowledge-focused Recruiting nowThis study looks at whether a rapid fingerstick test that gives results in 10-20 minutes can help more people get screened for HIV, hepatitis C, and syphilis during mobile clinic visits. About 200 patients of the WVU Street Medicine team can choose the rapid test, a traditional b…
Sponsor: West Virginia University • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Simple blood test may replace colonoscopy for colitis patients
Knowledge-focused Recruiting nowThis study is testing whether a blood test measuring a protein called LRG can tell if the gut lining has healed in people with ulcerative colitis. Researchers will compare blood LRG levels with colonoscopy and tissue samples in 100 patients. If the blood test works, it could offe…
Sponsor: Showa Inan General Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists launch major study to track rare immune diseases
Knowledge-focused Recruiting nowThis study is observing up to 3,500 people with immune system problems, including rare genetic conditions like chronic granulomatous disease and severe combined immunodeficiency. Researchers will track how these diseases change over time through blood tests, imaging, and checkups…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive meningitis study aims to improve care in brazil
Knowledge-focused Recruiting nowThis study is tracking how adults with meningitis are treated in about 30 hospitals across Brazil. Researchers will follow 624 patients during their hospital stay and after discharge to see what treatments work best and how patients recover. The goal is to gather real-world evide…
Sponsor: Hospital Israelita Albert Einstein • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Beyond the lungs: the hidden emotional toll of IPF medications
Knowledge-focused Recruiting nowThis study uses an online questionnaire to understand how side effects from antifibrotic medications affect the emotional and social well-being of patients with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) in Japan. Researchers will ask about patien…
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Massive lung disease registry aims to unlock secrets of progressive fibrosis
Knowledge-focused Recruiting nowThis registry is following 3,000 adults with idiopathic pulmonary fibrosis (IPF) or other chronic fibrosing interstitial lung diseases (ILDs) to understand how these conditions progress over time. Researchers collect information on symptoms, treatments, quality of life, and store…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New study screens for hidden genetic marker in mysterious mast cell disorders
Knowledge-focused Recruiting nowThis study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…
Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a patient registry unlock the secrets of IBD?
Knowledge-focused Recruiting nowThis study is building a registry of medical information from people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The goal is to use this data to better understand how IBD develops and progresses, which could help improve future treatme…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Could a simple blood test flag heart risk in rheumatoid arthritis?
Knowledge-focused Recruiting nowThis study looks at whether certain markers of oxidative stress in the blood are linked to early signs of heart disease in people with rheumatoid arthritis. Researchers will measure these markers and check for thickening or stiffness in the carotid arteries. The goal is to better…
Sponsor: University of La Laguna • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New imaging study aims to unlock secrets of lung scarring
Knowledge-focused Recruiting nowThis study tests whether two types of PET/CT scans can show inflammation and scarring in the lungs of people with idiopathic pulmonary fibrosis (IPF). Ten adults aged 40-85 with IPF will receive the scans. The goal is to help doctors better understand the disease and guide future…
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Ultrasound may predict which patients get poor pain relief from a common knee block
Knowledge-focused Recruiting nowAfter knee replacement, a nerve block called the adductor canal block is often used to control pain while preserving leg strength. But it does not work equally well for everyone. This study will examine whether ultrasound measurements—such as tissue depth and nerve visibility—can…
Sponsor: Konya City Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Saliva test may catch implant gum disease early
Knowledge-focused Recruiting nowThis study looks at whether certain substances in spit and fluid around dental implants can help detect a gum disease called peri-implantitis early. Researchers will compare 80 people with healthy gums, regular gum disease, or implant-related gum disease. The goal is to find bett…
Sponsor: Saglik Bilimleri Universitesi • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Hidden thyroid cancers may be more common in Graves' disease than thought
Knowledge-focused Recruiting nowThis study looks at how often thyroid cancer is found by accident when people with Graves' disease have their thyroid gland removed. Researchers will track 280 adults having this surgery and examine the removed tissue carefully for any cancer, including tiny microcarcinomas. They…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can pregnancy and neurological disease coexist safely? a new registry seeks answers
Knowledge-focused Recruiting nowThis study is a pregnancy registry that gathers information from women with chronic neurological conditions like multiple sclerosis, NMOSD, and myasthenia gravis who are planning pregnancy, currently pregnant, or within one year postpartum. Participants can contribute blood, brea…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can we predict how kids with IBD will respond to treatment?
Knowledge-focused Recruiting nowThis study follows 1,500 children newly diagnosed with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, to understand why some respond well to treatments while others develop complications. Researchers will collect medical data and biological sa…
Sponsor: Erasmus Medical Center • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
High-Altitude living: a hidden factor in esophageal health?
Knowledge-focused Recruiting nowThis study looks at the stomach and esophagus of people living at high altitude in Zaduo County, comparing them with similar patients from lower-altitude Jilin Province. The goal is to see if high-altitude residents have different patterns of conditions like reflux esophagitis an…
Sponsor: Jilin University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists to decode why common cold turns severe in kids
Knowledge-focused Recruiting nowThis study aims to find out how often rhinovirus (the virus behind many common colds) causes serious breathing problems that require hospital care in children. Researchers will follow 120 young children at home for 3 years and study 450 hospitalized infants and children, plus 100…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Finger-Prick test aims to uncover hidden hepatitis c cases
Knowledge-focused Recruiting nowThis study is testing whether a quick finger-stick test can help find more people with hepatitis C and get them into treatment. About 60,000 adults at risk for hepatitis C will take the test at clinics, shelters, or prisons. The study itself does not provide treatment, but will c…
Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New MRI technique could spot lung trouble early in transplant patients
Knowledge-focused Recruiting nowThis study is testing a new type of MRI that uses xenon gas to see how well the lungs are working in people who have had a bone marrow transplant. Researchers will scan 25 transplant patients with or without lung problems, plus 10 healthy volunteers. The goal is to see if this MR…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could your soap and food be making you sick? new study investigates
Knowledge-focused Recruiting nowThis study looks at how common chemicals in personal care products, processed foods, and synthetic materials affect skin, gut, and airway health. One hundred twenty healthy adults will stay in a controlled hospital room for two 7-day periods—one with filtered air and pure product…
Phase: NA • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists launch major study to unravel mysterious metabolism disorders
Knowledge-focused Recruiting nowThis study aims to learn more about rare disorders that affect how the body processes chemicals called pyrimidines and purines. These disorders can cause problems in the brain, blood, kidneys, and immune system, ranging from mild to life-threatening. Researchers will compare test…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can brain scans reveal the hidden toll of hidradenitis suppurativa?
Knowledge-focused Recruiting nowThis observational study uses brain imaging to explore whether people with hidradenitis suppurativa (HS) have differences in resting brain activity compared to healthy individuals. Researchers will also track how these brain patterns relate to disease severity, pain, sleep, mood,…
Sponsor: Second Xiangya Hospital of Central South University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could a symptom registry unmask hidden migraine variants?
Knowledge-focused Recruiting nowThis study is building a large online registry of US adults who experience sinus, ear, dizziness, and headache symptoms, with or without a migraine diagnosis. Participants answer questions about their symptoms, how these affect daily life, and which treatments they have tried. Th…
Sponsor: Association of Migraine Disorders • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists watch immune system in action to unlock IBD mysteries
Knowledge-focused Recruiting nowThis study aims to learn how the immune system controls inflammation in the gut for people with Crohn's disease or ulcerative colitis. Up to 1,000 participants aged 0 to 75 will receive standard medical care and may provide blood, tissue, or white blood cell samples. No experimen…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists launch major study to uncover secrets of kidney autoimmunity
Knowledge-focused Recruiting nowThis study follows up to 2000 people with immune-related kidney diseases, such as nephrotic syndrome and lupus nephritis. Researchers will collect medical history, lab tests, and blood or urine samples to better understand these conditions. The goal is to learn more about causes …
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Swimming pools may ease knee replacement wait: new study tests community program
Knowledge-focused Recruiting nowThis study looks at whether it's possible to run a larger trial of a community-based program called Good Boost+ for adults waiting for knee replacement surgery. The program includes weekly group water exercises and land-based exercises, plus peer support. Researchers will measure…
Phase: NA • Sponsor: King's College Hospital NHS Trust • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Could childhood trauma fuel skin inflammation?
Knowledge-focused Recruiting nowThis study investigates how inflammatory genes are regulated in people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Researchers will compare inflammatory markers in HS patients versus healthy controls. An optional sub-study explores whether …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
NIH launches training study for Hard-to-Diagnose infections and inflammation
Knowledge-focused Recruiting nowThis study enrolls up to 400 people with known or suspected infections or inflammatory diseases that are not covered by other research protocols. The goal is to evaluate patients using standard medical practices, generate new ideas for future studies, and train doctors. No experi…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists probe immune cell secrets in healthy volunteers
Knowledge-focused Recruiting nowThis study looks at how certain white blood cells (neutrophils and monocytes) sense signals in the body and what substances they release, especially when they might cause inflammation. Healthy adults aged 18 to 65 who weigh at least 110 pounds can join by donating blood up to six…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Gut bacteria during infection may flag IBS risk
Knowledge-focused Recruiting nowThis study looks at how a Campylobacter gut infection changes the bacteria and lining of the bowel, and whether these changes can help identify who might later develop irritable bowel syndrome (IBS). Researchers will follow people with a confirmed Campylobacter infection who do n…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Why do healthy people get this fungal infection? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at 800 healthy adults who have cryptococcosis, a fungal infection that usually only harms people with weak immune systems. Researchers want to learn why these otherwise healthy people get sick, how their immune system responds, and how the disease progresses over…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists probe how eczema drugs alter skin microbes
Knowledge-focused Recruiting nowThis study examines how common eczema treatments, including antibiotics and bleach baths, change the types and amounts of bacteria on the skin. Researchers will compare people with eczema to healthy volunteers. The goal is to understand the skin microbiome better, not to test a n…
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists dig into mouth bacteria to unlock immune secrets
Knowledge-focused Recruiting nowThis study looks at how genetic immune system problems might lead to gum disease and other mouth issues. Researchers will collect samples like saliva, plaque, and blood from 700 people, including those with immune defects, healthy adults with gum disease, and healthy adults witho…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can ultrasound reveal how knee ligaments change with osteoarthritis?
Knowledge-focused Recruiting nowThis study uses a special ultrasound technique called shear wave elastography to measure the stiffness of knee ligaments in healthy adults and in people with knee osteoarthritis. The goal is to establish normal stiffness values across different ethnic groups and to see how ligame…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Scientists launch major study to unravel mysteries of rare brain infection PML
Knowledge-focused Recruiting nowThis study follows 700 people with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Researchers will collect blood, spinal fluid, and brain scans over time to understand how the disease progresses. No treatment is given; the goal is…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Eczema registry aims to map Real-World treatment journeys
Knowledge-focused Recruiting nowThis study is a registry that will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments people use, how long they take them, and why they change or stop. The goal is to better unde…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Researchers check safety of stent grafts used in aortic aneurysm surgery
Knowledge-focused Recruiting nowThis study looks back at medical records of 105 people who had a minimally invasive surgery called BEVAR to treat complex aortic aneurysms. Researchers want to see if two types of stent grafts (TUVA BX and iCover) are safe and work well. No new treatments are given; the study jus…
Sponsor: JOTEC GmbH • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Scientists investigate hidden link between immune disorders and brain health
Knowledge-focused Recruiting nowThis study looks at how immune system diseases can cause problems in the brain and nerves, affecting movement, thinking, and feelings. Researchers will follow 350 people aged 2 and older with immune diseases, plus their healthy relatives, for up to 5 years. They will collect bloo…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Study probes why IBD meds work better for some groups
Knowledge-focused Recruiting nowThis study surveys 400 adults with inflammatory bowel disease (IBD) from two medical centers to understand how social factors like insurance, income, and support affect medication adherence and quality of life. Researchers focus on Hispanic and Black patients, who often have wors…
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can Real-World data unlock better skin disease care?
Knowledge-focused Recruiting nowThis observational study aims to collect and analyze data from up to two million patients with dermatologic conditions like vitiligo, atopic dermatitis, alopecia areata, and hidradenitis suppurativa, as well as their healthcare providers. By reviewing treatment patterns, outcomes…
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New device sucks up skin secrets to unlock baby eczema mysteries
Knowledge-focused Recruiting nowThis study will test a new, gentle device that collects fluid from the skin of babies up to 6 months old. Researchers want to see if it's comfortable and can measure chemical signals that may explain why some babies get eczema. By comparing healthy babies and those with eczema, t…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Lupus secrets revealed: major study tracks disease over time
Knowledge-focused Recruiting nowThis study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
NIH launches major study to uncover why rheumatic diseases hit minorities harder
Knowledge-focused Recruiting nowThis study aims to learn more about the causes of rheumatic diseases—conditions that cause joint pain, stiffness, and swelling—and why they often affect minority groups more severely. Researchers will observe up to 7,500 adults with known or suspected rheumatic disease, providing…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New study tracks hidden risks of hepatitis b drugs in vulnerable patients
Knowledge-focused Recruiting nowThis study follows 490 adults with a past hepatitis B infection who need immune-suppressing treatments. Researchers will monitor bone, kidney, and metabolic health over 4 years to understand the long-term side effects of antiviral drugs. The goal is to create better safety guidel…
Sponsor: Yaşar Bayındır, MD • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Eczema patients needed for study on improving treatment habits
Knowledge-focused Recruiting nowThis study aims to understand why many people with atopic dermatitis (eczema) don't use their topical medication as prescribed, which can lead to worse symptoms and higher healthcare costs. About 30 adults and children with active dermatitis will be divided into groups to receive…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists dig into skin healing mysteries in immune disorders
Knowledge-focused Recruiting nowThis study aims to understand how the immune system and skin healing are connected in people with primary immunodeficiency, psoriasis, or eczema, as well as in healthy volunteers. Researchers will collect skin biopsies, blood samples, and optional skin swabs to analyze microbes a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Lupus drug may harm ovaries – could a hormone shot help?
Knowledge-focused Recruiting nowThis study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Immune cell clues may predict sepsis outcomes
Knowledge-focused Recruiting nowThis completed observational study at a single hospital in China enrolled 16 adults with sepsis in the ICU. Researchers measured specific memory CD8+ T cells in the blood at several time points to see if their numbers or activity relate to how severe the sepsis is or whether pati…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
France launches massive virus surveillance in GP clinics
Knowledge-focused Recruiting nowThis study will track which respiratory viruses—like flu, COVID-19, and RSV—are circulating in French primary care clinics each winter. Up to 25,000 patients with cold or flu symptoms will provide a saliva or nose swab sample. The goal is to monitor virus activity and help guide …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Scientists track spondyloarthritis in families to uncover clues to severe disease
Knowledge-focused Recruiting nowThis study follows up to 2,000 people with spondyloarthritis (a group of inflammatory joint and spine conditions) and their healthy relatives. Researchers aim to identify symptoms, genetic factors, and medical tests that predict who will develop more severe forms of the disease. …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Scientists seek 2,000 volunteers to uncover how everyday exposures shape disease
Knowledge-focused Recruiting nowThis study aims to understand how environmental factors like pollution, diet, and stress contribute to human disease. Researchers will collect samples such as blood, urine, and skin from 2,000 healthy adults aged 18 and older. Participants may also complete surveys and provide ho…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Could a common sugar fuel liver damage?
Knowledge-focused Recruiting nowThis trial asks whether fructose, a sugar found in fruit and processed foods, causes more liver inflammation in people with MASH (a serious fatty liver disease) than in those with milder fatty liver or no liver disease. Over four weeks, participants follow a low-sugar diet and th…
Phase: NA • Sponsor: Queen Mary University of London • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can the chemical signature of gum disease be detected?
Knowledge-focused Recruiting nowThis study looks at whether gum disease (periodontitis) changes the chemical makeup of the fluid that seeps from the gums. Researchers will compare samples from 30 adults with periodontitis and 30 healthy adults, all aged 18 to 70. During a single dental visit, participants will …
Sponsor: University of Catania • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
HIV and fatty liver: a hidden link under the microscope
Knowledge-focused Recruiting nowThis study follows 250 people newly diagnosed with HIV and 161 healthy volunteers over five years to see who develops metabolic fatty liver disease (MASLD). Researchers use annual blood tests, ultrasounds, and FibroScans to measure liver fat and stiffness. The goal is to uncover …
Sponsor: Yaşar Bayındır, MD • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Hunting for hidden eye infections: a new diagnostic approach
Knowledge-focused Recruiting nowInfectious uveitis is a serious cause of blindness, but current tests often miss the culprit. This study uses a broad panel of molecular tests to detect bacteria, viruses, and fungi in eye fluid from 100 patients with suspected infectious uveitis in China. The goal is to map whic…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
Knowledge-focused Recruiting nowThis study follows 1500 Chinese adults with chronic hepatitis B, nonalcoholic fatty liver disease, or both, to see how having both conditions changes the risk of serious liver problems like cirrhosis, liver failure, and liver cancer. Researchers will track who develops these comp…
Sponsor: Humanity and Health Research Centre • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
10-Year quest to uncover fatty Liver's hidden toll in china
Knowledge-focused Recruiting nowThis 10-year observational study follows 20,000 Chinese adults with non-alcoholic fatty liver disease (NAFLD) or its more severe form, NASH. Researchers aim to measure how common these conditions are and how they progress over time. By collecting medical data and blood samples, t…
Sponsor: Humanity and Health Research Centre • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Artificial intelligence may help decide who gets a liver first
Knowledge-focused Recruiting nowThis study tests whether artificial intelligence can more accurately predict which patients on the liver transplant waiting list are at highest risk of dying or becoming too sick for surgery. Researchers will follow 630 adults with severe liver disease or liver cancer across five…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
AI may outsmart current system for liver transplant priority
Knowledge-focused Recruiting nowThis European study is collecting health data from 4,500 adults listed for liver transplantation across 50 centers. The goal is to design and test new AI-based models that predict which patients are most likely to die or become too sick for transplant while waiting. If accurate, …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Rare brain infection risk under scrutiny for multiple sclerosis drug ozanimod
Knowledge-focused Recruiting nowThis study investigates whether the multiple sclerosis medication ozanimod is linked to a higher risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by the John Cunningham virus. Researchers will review reported cases of PML in peop…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC